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Preface 
Frédéric Chopin is one of my favourite composers, as he combines romantic 
nostalgia with simplicity in the most ingenious manner. While I was working on my 
thesis, I immersed myself in several of his pieces and spent many hours in front of 
my piano, which is the best way for me to relax. During the work on my thesis I fell in 
love with the Piano Sonata No. 2 in B-flat minor, Op. 35, which he wrote in France 
during the years 1837-39. A part of this piece is shown here: 
 
Chopin was plagued by bad health. Above all he had a pulmonary disease that 
probably caused his death at the age of 39.  Chopin was a sensitive, reserved person 
with sudden attacks of melancholy, leading to the suggestion that he might have 
suffered from depression (Karenberg et al., 2007). Moreover, he suffered from 
hallucinations, as exemplified by an incident during a concert at a wealthy merchant’s 
private house in Manchester on August 29th 1848. While he was playing the Sonata 
No. 2, he suddenly stood up and left the room. Later he described this incident in a 
letter with the words: “… I had played the Allegro and the Scherzo … and was about 
to play the March (notes above) when, suddenly, I saw emerging from the half-open 
case of my piano those cursed creatures…” (Caruncho and Fernández, 2010). 
Episodes like these were not uncommon for Chopin, but he preferred to keep them to 
himself.  
As if specifically intended for this thesis, only shortly before submission of my work, a 
paper entitled “The hallucinations of Frédéric Chopin” was published in the journal 
“Medical Humanities” (Caruncho and Fernández, 2010). In this paper it is postulated 
for the first time that Chopin might have suffered from Temporal Lobe Epilepsy (TLE) 
– the condition of central interest to this thesis. Chopin’s complex hallucinatory 
episodes are reviewed in the article and found to be consistent with seizures typical 
for TLE. Indeed, the attacks described in the paper could be focal seizures, attended 
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by complex visual experiences and/or psychic symptoms. TLE is frequently 
accompanied by anxiety, fear, insomnia, and depression, all symptoms that 
characterised the personality of Chopin. 
Chopin once said “…Time is the best censor, and patience a most excellent teacher”, 
a sentence that also can be extrapolated to this thesis, and, indeed, to other 
important issues in life. 
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Translational research  
“Progress is often made at the interface of disciplines and in an environment of 
intellectual freedom” (Zerhouni et al., 2005). The idea of translational research 
embraces this philosophy. In the narrow sense, translational research can be 
considered as a way of thinking and conducting scientific research with the aim of 
translating new knowledge, mechanisms, and techniques that have been generated 
by basic science research into novel approaches for prevention, diagnosis, and 
treatment of disease, or, in reverse, testing hypotheses generated by clinical 
observation in the lab (Marincola et al., 2003). 
Translational research has become a centrepiece of Research Councils around the 
world. Governmental agencies as, for example, the National Institutes of Health 
(NIH) in the United States and the European Commissions, consider translational 
research a funding priority and annually increase their budgets for health-related 
translational programmes (Zerhouni et al., 2003). Academic centres, foundations, 
hospitals, and industry all establish translational research agendas, and several 
journals (e.g. Translational Medicine and The Journal of Translational Medicine) are 
committed to the subject. Inevitably the question arises: “what this is all about?” and 
“why is the translational approach promising?” The answer is simple.  The rate of 
translation of basic science promises into clinical applications over the past 
decades has been disappointing and inefficient (Contopoulos-Ioannidis et al., 
2003). In addition, it has been confirmed that a large quantity of clinical research 
resulted in the generation of information that was incorrect, obsolete, or even 
hazardous to human health (Antman et al. 1992).  A bidirectional flow of information 
and multidisciplinary competence should be a powerful tool to address these 
inadequacies and one that is necessary in order to progress in our understanding of 
biological systems (Ioannidis et al. 2004). In the light of a growing awareness of the 
extreme complexity in the patterns of aetiology and pathogenesis in common 
diseases, the translational research approach seems, at least, to have a chance of 
providing benefit to human health and wellbeing.  
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Objectives of this thesis 
 
Epilepsy comprises a range of different chronic brain disorders and syndromes 
characterised by spontaneous, recurrent, unprovoked seizures. Worldwide, epilepsy 
affects 50 million people, or between 0.7 and 1 % of the global population, occurring 
in all ages and in all socioeconomic groups (Zarrelli et al., 1999). According to the 
WHO, epilepsy accounts for 1 % of the global burden of disease, equivalent to breast 
cancer in women or lung cancer in men (http://www.who.int).    
Aside from the impairment caused by the seizures themselves, epilepsy also 
interferes to a considerable extent with the normal activities of daily living, 
employment status, reproductive function, and social relationships, and is a 
significant risk factor for depression, serious injury, and death.  
While 2/3 of all epilepsy patients respond successfully to currently available 
antiepileptic drugs (AEDs), 1/3 continues to have recurrent seizures despite 
optimised pharmacological treatment (Kwan and Brodie, 2000). These 
pharmacoresistant cases are mainly represented by patients suffering from Temporal 
Lobe Epilepsy (TLE), traditionally defined by seizure origin in, or involvement of, the 
temporal lobe. These patients should derive benefit from new therapies that will 
produce greater efficacy than current medications. As a prerequisite to fulfilling the 
unmet medical needs of patients with TLE, a clear delineation of the phenotypes, 
genotypes, and molecular pathways that underlie the generation or development of 
epileptic seizures is required. 
Current antiepileptic treatment concepts are mainly based on the principle that 
epileptic seizures arise from abnormal excessive or synchronous neuronal activity in 
the brain. Undeniably, epileptic seizures could not occur without neurons. However, 
evidence has accumulated over recent years that proper neuronal functioning is not 
possible without the most abundant cell type in the brain, the glial cells. Glial cells, 
and especially astrocytes, are critically involved in maintenance of ion and water 
homeostasis, and hence in the pathophysiological mechanisms that lead to neuronal 
hyperexcitability and epilepsy (Seiffert et al., 2006). This makes glial cells an exciting 
subject for novel treatment concepts in epilepsy, especially in pharmacoresistant 
TLE.  
Investigation of the molecular function of glial targets, and searching for genetic 
associations in hypothetical candidate genes, will assist in our understanding of the 
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pathogenic mechanisms in epilepsy, and specifically in subgroups of TLE. To 
contribute to this search is the primary goal of this thesis.  
Detection of novel therapeutic targets for TLE is best performed by a translational 
research approach, as applied in this thesis, including: 
 
1) Phenotype studies that aim to filter out clinically distinct subgroups on the 
basis of demographic data and common phenotypic features from a 
principally unselected TLE population. This facilitates genetic and 
biomedical research, which, in turn, provides a basis for tailored 
pharmacological treatment and improved outcome. 
2) Genetic association studies in TLE subpopulations on candidate genes 
based on plausible a priori hypotheses, derived from biomedical or 
clinical/epidemiological research. 
3) Biomedical research on glial/astrocyte targets in the TLE field, based on 
novel general concepts and on indications derived from own genetic and 
clinical studies. 
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1. Introduction 
 
1.1 The clinical picture of Temporal Lobe Epilepsy 
 
1.1.1 Definition and classification 
The classification of Temporal Lobe Epilepsy (TLE) has been frequently refined over 
the years, and the latest version is most probably only temporary also. These 
intermittent modifications have caused, and still cause, confusion. In the ILAE 
classification of 1985, TLE was defined as recurrent unprovoked seizures with origin 
in the temporal lobe (Proposal for classification of epilepsies and epileptic 
syndromes, 1985) With this definition, TLE was characterised as one of 5 
symptomatic, localisation-related epilepsies, in which seizure semiology and epileptic 
activity in EEG define a link to a circumscribed anatomical region of the brain. 
According to the location where seizures arise, TLE was further divided into lateral 
(or neocortical) temporal lobe epilepsy (LTLE or NTLE) and medial/mesial temporal 
lobe epilepsy (MTLE). One principal pitfall is embodied in this anatomical 
classification, as the site of actual seizure origin may be at considerable distance 
from the region that gives rise to clinical symptoms (Lee et al., 2000). Hence, the 
revised classification of 1989 moved away from the anatomical classification and 
defined TLE on the basis of typical clinical features, and EEG and imaging findings 
(Proposal for revised classification of epilepsies and epileptic syndromes, 1989). 
However, the 1989 classification did not consider the aetiology or pathogenesis of 
TLE. TLE, in fact, denotes a variety of conditions with different aetiological 
backgrounds, most of which still are elusive.  
The latest classification, published just last year, omits TLE as a separate category 
(Berg et al.2010), and instead highlights only familial temporal lobe epilepsies as a 
definite subgroup among electroclinical syndromes of adolescents/adults. In addition, 
mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS) is included as 
a distinctive constellation. 
The latest classification also encompasses a number of conceptual modifications. 
According to current knowledge, all epileptic seizures involve neuronal networks in 
one or both hemispheres, engaging both cortical and subcortical structures. On the 
basis of this concept, the terms “focal” and “generalised” seizures have been 
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redefined. Thus, until further re-classification “focal” indicates that seizures primarily 
arise in one cerebral hemisphere, either in circumscribed areas, or with a wider 
distribution, while the term “generalised” refers to seizure generation in bilateral 
networks. Furthermore, the distinction between “simple partial” and “complex partial” 
seizures has been discarded, and the term “partial” is now to be used synonymously 
with “focal”. 
These latest modifications may lead to confusion, including with respect to this thesis. 
For practical reasons, both definitions are used in the text of this thesis. 
 
1.1.2 Historical notes 
The English neurologist John Hughlings Jackson (1835-1911) is usually credited with 
being the first to recognise TLE. Through his description of “uncinate group of fits” 
and the “dreamy state” (over-consciousness or heightened intellectual state) in 1880, 
Jackson presented the first characterisation of TLE with medial seizure origin 
(Jackson, 1880; Jackson 1898; Hogan RE et al., 2003). Parallel to the work of 
Jackson, the German neuropsychiatrist and pathologist Wilhelm Sommer (1852-
1900) reported evidence for a causal relationship between epilepsy and lesions in the 
hippocampus in an extensive autopsy material (Sommer, 1880). Sommer’s studies 
were extended by detailed histological observations by the German psychiatrist and 
neurologist Emil Bratz (1867-1934), who was the first to describe the characteristic 
morphological changes in hippocampal sclerosis (HS) (Bratz, 1899). The invention of 
EEG in the early 20th century contributed to increasing further our recognition and 
understanding of TLE. In 1937, the American neurologist Frederic A. Gibbs (1903-
1992) introduced the term “psychomotor attacks” to describe the signs and symptoms 
of seizures with temporal lobe origin, and contributed to the general understanding of 
epilepsy as a state based on paroxysmal cerebral dysrhythmia (Gibbs et al., 1937). 
By the middle of the 20th century, TLE was widely established as a distinctive 
epileptic condition, partly due to the observation of focal temporal sharp waves in 
EEG of patients with clinically characteristic seizures (Jasper and Kershman, 1941). 
The first operations on patients with TLE were performed by Gibbs in 1951 and, 
shortly afterwards, by Falconer in the beginning of the fifties (Bailey and Gibbs, 1951; 
Falconer, 1953). As tissue from operated patients was available for investigation, 
extensive knowledge on pathological features in the epileptic hippocampus could be 
obtained. However, despite intensive research, the distinct role of the hippocampus 
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in the generation of seizures and the development of epilepsy remains unresolved, 
even today.  
 
1.1.3 Epidemiology 
It is often reported that 40 % of epilepsy patients experience complex partial seizures 
(CPS) (according to the previous classification), which are usually associated with 
seizure origin in the temporal lobe (Engel J Jr, et al., 2003). Naturally, this definition 
has limitations, as not all patients with CPS suffer from TLE. Moreover, it is often 
stated that one third of all epilepsy patients have TLE, but there is no conclusive 
evidence that this is correct. 
A prerequisite of all epidemiological studies is clear definition of the population of 
interest. However, as described, TLE comprises a large variety of different entities 
with different aetiological backgrounds, most of which are still elusive. Another 
confusing factor is the frequent changes in definitions and classifications. This 
undermines epidemiological approaches, and means that there are no definitive 
epidemiological data on TLE. As MTLE-HS has recently been described as a 
distinctive entity (Wieser et al., 2004) appropriate epidemiological studies on this 
syndrome should now be possible. However, data about MTLE-HS are usually 
derived from large centres and generally focus upon surgically-treated patients 
and/or the most medically intractable cases. Information on mild forms of MTLE-HS is 
difficult to obtain, complicating the assembly of valid epidemiological data. 
 
1.1.4 Anatomy of the hippocampus  
The hippocampus plays an important role in the consolidation of information from 
short-term memory to long-term memory, and in spatial navigation. The hippocampal 
formation is located in the basomedial part of the temporal lobe of the brain and 
constitutes a major part of the archicortex and the limbic system. A cross section 
perpendicular to the long axis of the structure reveals the internal structure as two 
interlocking “C” shapes, one of which comprises the cornu ammonis (CA), the other 
makes up the dentate gyrus. The CA can be further segregated according to the 
anatomical classification by Lorente de No, (1934), in subregions CA1 – CA4. The 
CA is comprised of several layers as illustrated in figure 1.  
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Figure 1: Main layers in the hippocampus proper
Alveus: most superficial layer and contains commissural fibers of pyramidal cells via the fimbria. 
Stratum Oriens: contains inhibitory basket cells and the basal dendrites of pyramidal neurons 
(innervated by recurrent collaterals and contralateral hippocampus). 
Stratum Pyramidale: contains the somas of pyramidal neurons. Mossy fibers (MFs) also synapse in 
this layer. 
Stratum Lucidum: mossy fibres transverse and terminate in this region. 
Stratum Radiatum: contains the Schaffer collaterals of CA3-1 pathway. 
Stratum Lacunosum-Moleculare: also contains some fibers from the Schaffer collaterals.  
 
The hippocampus has plenty of connections to and from surrounding brain regions. 
Afferent pathways to the hippocampus have their origin in the posterior parietal 
association cortex (area 7) and from the adjacent temporal and occipital regions 
(areas 22, 39, and 40). Most afferences penetrate the hippocampus via the 
entorhinal cortex. Moreover, direct afferences from amygdala also exist, from the 
hypothalamus, the septum region, and from the contralateral hippocampus via fornix.     
The efferences of the hippocampus exit via alveus and fimbria towards the same 
regions from which the afferences originate. 
Pathological changes of the hippocampus are typical for the syndrome of MTLE-HS, 
which is described in the following chapter.  
Large textbooks have been written about the anatomy of the hippocampus. To detail 
the anatomical structure and integration of the hippocampus is not intended at this 
point. A comprehensive survey about hippocampal anatomy can, for example, be 
found in Per Andersen´s textbook entitled Hippocampus (Andersen, ed. 2007).
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1.1.5 Mesial Temporal Lobe Epilepsy with hippocampal sclerosis 
The hippocampus is one of the most studied anatomical regions of the brain, and 
hippocampal sclerosis (HS or Ammon´s horn sclerosis) the most explored 
“epileptogenic lesion”. It is therefore not possible to review here all aspects of the 
extensive literature in this field. Over the years, evidence has accumulated that 
MTLE-HS may constitute a distinctive syndrome. In 2004, a panel consisting of 
leading experts discussed the definition, natural history, pathological features, 
pathogenesis, electroclinical, neurophysiological, neuropsychological, structural, and 
functional imaging features, as well as surgical outcomes in patients with HS and 
mesial seizure origin (MTLE-HS) (Wieser et al., 2004). This resulted in a consensus, 
in which MTLE-HS was considered to represent “a sufficient cluster of signs and 
symptoms to make up a syndromic diagnostic entity”. This chapter focuses only on 
the main aetiological, histopathological, clinical, diagnostic, and treatment features of 
MTLE-HS.  
 
Aetiology and basic mechanisms 
The epileptogenic potential of MTLE-HS is a result of a large variety of changes in 
the hippocampus, foremost being neuronal cell loss, proliferation of glial cells, and 
synaptic reorganisation. However, whether these changes are the causes or 
consequences of epileptic seizures, and the order in which they appear, have been 
issues of debate for decades.  
Retrospective studies of surgically-treated patients have revealed a high occurrence 
of early childhood incidents. These events, also referred as to “initial precipitating 
incidents (IPI)”, include febrile seizures, hypoxia, trauma, and intracranial infections. 
While identified in several retrospective studies, no prospective study yet exists that 
confirms these results (Mathern et al., 1995). A large number of mechanisms through 
which epileptogenesis may develop in MTLE-HS have been suggested. These 
include: glutamate neurotoxicity, mitochondrial dysfunction, immunological 
responses, genetic predisposition, and multiple acquired factors. To detail all these 
mechanisms would go far beyond the scope of this thesis. However, a fascinating 
story emerges from novel concepts that bring together glial dysfunction and disease 
development in neurological diseases. With regard to epilepsy, it is suggested that 
modified astroglial function may have an important role in the generation and spread 
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of seizure activity. To study this new idea of glia-mediated epileptogenesis is the 
primary objective of this thesis and is elaborated in detail in subsequent sections.  
 
Main histopathological findings 
The term sclerosis is based on the macroscopic finding of a shrunken, indurated 
hippocampus, and had already been described in the first quarter of the 19th century 
(Bouchet and Cazauvielh, 1825). The principal histological findings of HS can be 
dated back to the descriptions of Sommer and Bratz at the end of the 19th century, as 
previously mentioned (Sommer, 1880; Bratz, 1899). The histopathological hallmarks 
of MTLE-HS include segmental pyramidal neuron loss, glia cell proliferation, and 
dispersion of granular cells. The ILAE commission report on MTLE with HS (Wieser 
et al., 2004) proposed the typical pathological changes in HS, as listed here: 
1.) As minimal criteria, neuronal loss, and gliosis predominantly involve CA1 and end-
folium (CA3 and CA4) with relative sparing of the CA2 and subiculum.  
2.) All hippocampal regions may show cell loss and gliosis to varying degrees. 
3.) Functional and structural glial changes appear. 
4.) Synaptic reorganisation often occurs. 
5.) Dentate (granular cell) dispersion is encountered in more than 50 % of cases. 
6.) Extrahippocampal pathology at other mesial temporal lobe structures, e.g. 
amygdala. 
7.) Other pathological findings may be found, depending on which staining 
techniques are used. 
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Figure 2: Nissl stained coronal sections of human hippocampus formations from autopsy (left) 
and from a patient with MTLE-HS (here referred to as MTLE, right) 
The autopsy hippocampus shows a normal anatomical structure, whereas the MTLE hippocampus is 
smaller due to sclerosis and shows typical histopathological changes as loss of neurons, especially in 
CA1, glial proliferation, and granular cell dispersion in the hilar granular cell layer. 
 
Clinical phenomenology 
The archetypical medical history of patients with MTLE-HS starts with an IPI in early 
childhood, followed by a latent period of variable duration without any apparent 
clinical signs or symptoms, before habitual seizures occur. Habitual seizures often 
arise towards the end of the second decade of life, and tend to occur earlier in MTLE-
HS than in other TLE/MTLE patients. (Davies et al., 1996; Janszky et al., 2004; 
Villanueva et al., 2005). Habitual seizures may initially respond to pharmacological 
treatment, but, over time, become more and more refractory (Semah et al. 1998). 
The progressive nature of this clinical presentation has been the subject of vigorous 
debate. Given that MTLE-HS worsens with time, could this process be affected or 
delayed by any kind of pharmacological or non-pharmacological treatment? Animal 
kindling models support a progressive course, as recurrent seizures lead to synaptic 
reorganisation and neuropathological changes in the hippocampus comparable with 
those of HS in humans (Sutula T et al., 1988). The degree of hippocampal atrophy 
may correlate with changes in magnetic resonance imaging (MRI), further supporting 
the worsening nature of the condition (Cendes F et al., 1993). However, evidence of 
HS is not necessarily related to seizure severity and may occur in individuals who 
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never experience seizures (Kobayashi et al., 2002). It is important to remember that 
benign forms of MTLE-HS also exist, which are readily controllable with common 
AEDs. Most studies, however, generate results from surgically treated MTLE-HS 
individuals, who represent the most pharmacoresistant cases. 
 
Mood disturbance and cognitive impairment 
The mesial temporal region participates in emotional expression and is implicated in 
mood disturbances. Interictal depression is a frequent psychiatric symptom in 
epilepsy and has been related to epilepsy of temporal origin (Mendez et al. 1986; 
Gaitatzis et al., 2004). However, whether depression occurs more frequently in 
MTLE-HS than in other TLEs is still a subject of debate. Some studies implicate 
depressive symptoms more frequently in MTLE-HS, while others find no evidence of 
a specific temporal target region for depressive mood (Quiske et al., 2000; 
Helmstaedter et al., 2004). 
There is ample evidence of cognitive impairment in MTLE-HS. Typically, MTLE is 
associated with impairment of episodic memory, which means that retrieval of newly 
acquired information or consolidation of long-term memory is affected (Hermann et 
al., 1997). Some imaging studies confirm that the degree of memory disturbance 
correlates, to some extent, with the severity of hippocampal atrophy in MTLE-HS 
(Baxendale et al., 1998; Sawrie et al. 2001). Other determinants of memory 
disturbance are age of onset and severity of the epilepsy, additional 
extrahippocampal brain lesions (dual pathology), and use of AEDs. However, data 
concerning the latter aspects are too limited to reach any definitive conclusions.  
In summary, MTLE-HS is most probably associated with mood disturbance and 
memory deficits. However, data assessment is difficult and determining whether 
these features are primary phenomena or secondary sequelae due to psychosocial 
aspects or use of AEDs, is problematic. Further studies are required to provide 
convincing evidence, and possible confounding factors have to be taken into 
account.  
 
Seizure characteristics 
Many descriptions of ictal and postical clinical signs and symptoms in MTLE have 
been published, and, for practical reasons, will be mentioned only superficially here. 
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MTLE is commonly associated with focal seizures (SPS and CPS, according to prior 
classifications). As there are no pathognomonic clinical signs, it is difficult to 
distinguish between seizures associated with MTLE-HS and seizures due to other 
MTLE, despite some studies that propose separability (Saygi S et al., 1994). Ictal 
characteristics can be divided into subjective and objective components.  
Subjective epileptic events are referred to as aura. The majority of MTLE patients 
experience auras (French et al., 1993) Auras may occur as isolated phenomena 
(prior SPS), or occur as a first manifestation of focal seizures that involve larger 
networks (prior CPS) (Sperling et al., 1989). The most frequent aura in MTLE is 
characterised by visceral sensations, often experienced as a rising sensation in the 
epigastric region (Duncan et al., 1987; French et al., 1993). Other aura subtypes 
comprise anxiety, déjà vu and jamais vu, olfactory hallucinations, micropsia and 
macropsia, and feelings of depersonalisation.  
Objective ictal manifestations of MTLE usually involve impairment of consciousness. 
These commonly begin with motor arrest, staring, and pupillary dilatation, before 
evolving to coordinated motor activities, referred as to automatisms. Automatisms are 
often of the oro-alimentary type (chewing, licking, lip-smacking, and tooth grinding), 
or present with stereotyped movements such as gesticulating and fumbling, or, less 
frequently, vocalisation, spitting, and bicycling movements. 
Other objective manifestations, that may have some localizing and lateralizing value, 
and are often associated with seizure spread to suprasylvian brain areas, are head 
and eye deviation, unilateral or contra-lateral tonic or dystonic posturing (Kotagal et 
al., 1989), ictal vomiting (Kramer et al., 1988), unilateral eye blinking (Benbadis et al., 
1996), and language disturbances such as aphasia, speech arrest, or vocalisation 
(Yen et al., 1996). Secondary generalisation occurs in MTLE, but usually shows 
variations of the classic tonic-clonic semiology (Wieser et al., 2004). Postictally, 
patients with MTLE often display visual relaxation, aphasia, confusion, and, 
exceptionally, motor deficits (Theodore et al., 1983). 
The clinical phenomenology and seizure semiology of MTLE-HS form the basis for 
establishing the diagnosis. EEG and imaging is not a centrepiece of this thesis, and 
therefore will not be discussed here.  
The diagnosis of MTLE-HS cannot be established on the basis of one or few criteria. 
It requires a constellation of signs and symptoms, together with EEG and imaging 
findings, neuropsychological data, and careful evaluation of patient history. 
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Treatment and outcome 
To the author’s knowledge, no systematic comparative studies on the 
pharmacological treatment of MTLE-HS have been conducted. Medical treatment, 
therefore, includes most of the current AEDs, preferably those with documented 
effect on focal seizures, such as carbamazepine, oxcarbamazepine, lamotrigine, 
levetiracetam and topiramate, but also valproate, phenytoin, phenobarbital, 
zonisamide, and others. The efficacy of a specific AED at controlling MTLE-HS may 
last for several years, until the condition becomes increasingly refractory (Berg et al., 
2003). The diagnosis of MTLE-HS is often not established until the patient attends a 
tertiary centre due to the lack of effect from medication. For this reason, no definitive 
information exists on the proportion of patients whose condition remains adequately 
controlled by pharmacotherapy.  
For medically resistant patients, surgical anteromesial temporal lobectomy is the 
treatment of choice and has been proven successful (McIntosh et al. 2001; Engel J Jr 
et al., 2003) Surgical treatment of patients with TLE has been reviewed extensively 
with particular focus on predictors of outcome (McIntosh et al., 2001). MTLE-HS has 
been identified as having a better surgical outcome than other forms of TLE (Berkovic 
et al. 1995; Lee et al., 1998). Moreover, a history of febrile convulsions in childhood 
has been reported to be significantly associated with a good seizure control outcome 
(Wieshmann et al., 2008). Febrile seizures are most likely to be associated with 
MTLE-HS, as elaborated in subsequent sections. 
 
1.1.6 Febrile seizures 
Febrile seizures (FS) are the most frequent type of convulsions in childhood. A febrile 
seizure is defined as “an event in infancy or early childhood, usually occurring 
between three months and five years of age, associated with fever but without 
evidence of intracranial infection or other defined cause” (NIH, 1980). FS should be 
distinguished from epilepsy, which is defined by recurrent non-febrile seizures.  
FS are usually grouped into simple and complex types. Simple FS are short, non-
recurrent, generalised tonic-clonic seizures of less than 15 minutes duration. Simple 
FS account for approximately 75 % of all FS and occur, per definitionem, before the 
6th birthday. Complex FS are usually prolonged and often recur up to several times 
within a 24-hour period. They may lead to focal or generalised seizures or even to 
febrile status epilepticus (SE) (Jones et al., 2007) 
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The cumulative incidence of FS shows regional variation, with 2-5 % in Europe and 
USA, 6-9 % in Japan, and, the highest, 14 % in Guam in the Pacific Ocean 
(Stanhope et al., 1972; Tsuboi et al., 1984; Hauser et al., 1994; Hauser et al., 1996) 
These regional epidemiological differences strongly indicate a genetic propensity for 
the occurrence of FS (Hauser et al., 1985; Tsuboi et al. 1991; Vestergaard et al. 
2002). This is supported by family and twin studies that have shown an increased risk 
for relatives, in comparison with the general population (Tsuboi, 1977; Tsuboi et al., 
1991). Either a polygenetic inheritance mode or autosomal dominant inheritance with 
incomplete penetrance has been discussed (Rich et al., 1987; Johnson et al., 1996). 
Although no specific genes that account for the majority of FS cases have been 
identified, family linkage studies have, to date, identified a total of 9 genetic loci 
(FEB1-9) for FS susceptibility (Nakayama et al., 2009). Furthermore, a number of 
association studies have been conducted and revealed 7 genes related to this 
condition (Nakayama et al., 2009; http//www.epigad.org). However, most association 
studies do not fulfil stringent criteria, are statistically underpowered, or lack replication 
(Tan et al., 2004; Nakayama et al., 2009). 
A genetic predisposition accounts for the highest predictive factor for the 
development of FS. However, a variety of other risk factors have been identified, 
including low plasma ferritin levels (Pisacane et al., 1996), high fever, retarded 
development and low birth weight (Vestergaard et al., 2002), and HHV6 or influenza 
A infections (Milichap et al., 2006; Suga S et al. 2007). The pathophysiology of FS is 
unknown. As febrile seizure susceptibility is highest in young children and decreases 
significantly with advancing age, developmental factors probably play an important 
role (Jensen and Baram, 2000). 
 
1.1.7 Febrile seizure-related epilepsies  
Generalised epilepsy with febrile seizures + (GEFS+) 
GEFS+ is an autosomal dominant familial syndrome with high penetrance, 
characterised by heterogeneous, mainly generalised, seizure phenotypes (Scheffer 
et al., 1997). Febrile seizures often persists beyond the usual age of 6 years (FS+), 
and patients may present with afebrile, generalised or focal seizures, and cases 
associated with severe myoclonic epilepsy in infancy (SMEI) have also been 
described. Different gene mutations have been identified, three of which involve 
subunits of the voltage gated sodium channels, SCN1 and SCN2, and two within 
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genes encoding subunits of the GABAA receptor (Wallace et al., 1998; Escayg et al., 
2000; Sugawara et al. 2001; Baulac et al., 2001; Dibbens et al., 2004). However, 
screening for these genes in FS populations has failed to detect an association 
(Nakayama et al., 2003). 
 
Severe myoclonic epilepsy in infancy (Dravet syndrome) 
SMEI is a serious epileptic syndrome that arises in the first year of life, often with 
prolonged, focal seizures often preceded by a relatively mild fever. SMEI is 
associated with developmental delay at around 1 year of age, accompanied by other 
afebrile seizure types, such as myoclonic, atypical absences, as well as ataxia and 
behavioural problems. SMEI may be analogous to GEFS+, and the discovery of 
mutations in the same SCN1A channel genes supports this theory (Ohmori et al., 
2002; Wallace et al., 2003). 
 
1.1.8 Association between MTLE-HS and febrile seizures 
About 13 % of all patients with epilepsy experience FS in childhood, with large 
variation between the different epilepsy syndromes (Hamati-Haddad et al., 1998). 
The strongest association has been postulated to exist between FS and TLE (25 %), 
especially with refractory MTLE-HS (50-80 %) (French et al., 1993; Maher et al., 
1995). This strong association supports the theory that FS may lead to hippocampal 
injury and subsequent unprovoked seizures. However, whether FS precipitate HS, or 
vice versa, (i.e., hippocampal alterations lead to FS), has been a key question for 
several decades. 
Retrospective studies of patients with TLE, and particularly with MTLE-HS, usually 
show a high association with FS in infancy (Cendes et al., 1993; French et al., 1993). 
A large variety of prospective studies, including many MRI studies, have been 
conducted to determine whether FS precipitate hippocampal injury and subsequent 
MTLE-HS. Most prospective studies do not confirm a link between FS and MTLE-HS 
(Camfield et al. 1994; Tarkka et al.; 2003), but other studies indicate the opposite 
(Farrow et al., 2006; Vestergaard et al. 2007). 
Lately, data from genetic studies have contributed to reinforcing a link between FS 
and MTLE-HS. A high incidence of FS in familial MTLE supports a common genetic 
basis (Berkovic et al. 1996; Hedera et al., 2007). Moreover, patients with TLE and a 
history of FS (TLE-FS) have a higher frequency of first grade family members with FS 
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(Briellmann et al., 2001), and mutations have been associated with simple FS, 
hippocampal abnormalities, and TLE (Colosimo E et al., 2007).  
Animal studies have been important tools for investigations of whether FS have the 
potential to result in epilepsy in the absence of genetic or acquired predisposing 
factors. A large variety of animal studies have shown that rodents exposed to 
hyperthermia develop spontaneous unprovoked seizures and pathological changes 
in the hippocampus that are comparable to those in patients with MTLE-HS (Dube et 
al., 2010; Scantlebury et al., 2010; McClelland et al., 2011).  
However, there is no evidence for the theory that complex FS imperatively leads to 
hippocampal alteration and subsequent MTLE, and a simple equation should be 
considered by those who advocate adoption of this idea:  
2-6 % of children in western countries develop febrile seizures, of which complex FS 
account for a fraction (approximately 15 %), suggesting that the incidence of complex 
FS is 1:300. However, MTLE-HS is significantly less frequent. The relationship 
between FS, hippocampal sclerosis, and the development of MTLE is complex, and 
probably depends upon multiple factors, most of which are still elusive. 
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1.2  Genetics of temporal lobe epilepsy 
 
Until the mid 1990s the majority of clinicians and scientists considered TLE to be an 
acquired disorder. However, recent evidence has refuted this concept and today we 
know that genetic factors play an important role. 
 
1.2.1 Historical notes 
In 400 BC, Hippocrates wrote the following on epilepsy in his manuscript On the 
Sacred Disease: “It begins to be formed while the foetus is still in utero” (Page TE et 
al., 1967). Taking into account that general medical knowledge was still in its infancy, 
this statement could be considered the first noted recognition of inherited 
components in epilepsy. Unfortunately, the realisation that epilepsy can be passed 
from one generation to the next, led to the implementation of marriage restrictions for 
people suffering from epilepsy. Even as recently as December 1999, India for 
example had a law regarding epilepsy and marriages in its Hindu marriage act, 
constituting that marriage could only be solemnised “if, at the time of marriage, 
neither party suffers from recurrent attacks of insanity or epilepsy”. 
A pioneer of the “modern” epilepsy genetics field was the American neurologist and 
former president of the ILAE, William Gordon Lennox (1884-1960). Lennox started 
investigating twins and families with epilepsy in the mid-1930s and his enthusiastic 
recruitment of twin pairs with epilepsy, resulted in the publication in 1960 of his 
classic manuscript entitled “The genetics of epilepsy” (Lennox and Lennox, 1960) 
With his assembly of 225 twin pairs, Lennox was able to prove the existence of 
heritable genetic factors in epilepsy. The notably higher concordance rate in 
monozygotic, compared with dizygotic twins in different epilepsy phenotypes was 
probably his most important observation (Vadlamudi et al., 2004). Lennox also 
understood that genetic factors alone could not explain his findings, and he 
anticipated the presence of exogenous factors, in conjunction with heritable factors, 
being of causative importance in epilepsy. With his observations, Lennox paved the 
way for the “multifactorial concept of inheritance” of the epilepsies, which is still alive 
today. 
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1.2.2 Genetic classification of the epilepsies 
Classifications that attempt to encompass the genetic background of the epilepsies 
commonly apply the following categorisation (Johnson et al., 2001; Reid et al., 2009): 
1) Epileptic seizures arising in the context of multi-organ hereditary disorders. 
These include chromosome disorders, neurocutaneous disorders, 
neurodegenerative disorders, genetic disorders of cortical development, and a 
large assortment of metabolic diseases.  
2) Idiopathic epilepsies with simple Mendelian inheritance. These are rare (1-2 %) 
epilepsies, based on a single mutant gene, and can be passed on to the next 
generation in several ways: autosomal dominant or recessive, X-linked 
dominant or recessive, Y-linked or mitochondrial. Most mutations in epilepsies 
have been found in different ion channel genes. 
3) Idiopathic epilepsies associated with cytogenetic (chromosomal) abnormalities. 
These are epilepsies based on de novo gene mutations, without heritable 
factors. 
4) Epilepsies with complex inheritance, involving multiple contributing factors. 
These epilepsies account for at least 50 % of all epilepsies, and include most 
forms of idiopathic generalised epilepsies, as well as partial epilepsies, and 
also encompass the TLE. 
 
All these categories may, in the broadest sense, include TLE cases. However, most 
TLE cases involve complex inheritance patterns and, therefore, belong in category 4. 
However, there is a growing list of several forms of familial temporal lobe epilepsies 
(FTLE) that could, at least in part, be consistent with category 2. For practical 
reasons, FTLE will be discussed here first.  
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1.2.3 Familial temporal lobe epilepsy (FTLE) 
A family history of epilepsy is not uncommon in patients with TLE. However, familial 
TLE do not comprise a single syndrome. Different forms of familial TLE exist, and it is 
crucial to conduct a detailed family anamnesis in order to define the familial epilepsy 
syndrome. Familial forms of TLE are now included in the latest classification of 
epileptic syndromes by the ILAE (Berg et al., 2010). Familial and sporadic (non-
familial) TLE cannot be distinguished on the basis of their clinical presentations, as 
there are no specific phenotypic characteristics. Hence, the family history has to be 
apparent. In the absence of any other suspected generalised or dominant partial 
epilepsy, at least two family members have to be affected to for a diagnosis of a 
familial form of TLE to be established. 
FTLE can be subdivided into two main, genetically distinct syndromes: mesial 
(FMTLE) and lateral/neocortical (FLTLE), depending on seizure onset, semiology, 
and MRI features. 
 
Familial lateral temporal lobe epilepsy (FLTLE) 
FLTLE is also termed autosomal-dominant partial epilepsy with auditory features 
(ADPEAF), and was first described by Ottman et al. in 1995 (Ottman et al., 1995). 
Clinically, this condition presents with auditory auras, characterised by ringing or 
humming sounds, followed by early ictal aphasia. Onset is in the first three decades 
of life. There is no association with febrile seizures, and MRI is usually normal. The 
course of the disease is benign (Winawer et al., 2000). Linkage analysis has revealed 
a locus on chromosome 10q24, and this later emerged as the locus of the leucine 
rich glioma-inactivated gene 1 (LGI1) (Kalachikov et al., 2002).  Similar families, 
mapping to the same region, have been described by Norwegian epileptologists, but 
with a somewhat different clinical picture, with prominent visual symptoms and 
sensory dysphasia due to lateral temporal lobe origin (Poza et al., 1999; Brodtkorb et 
al., 2002). To date, a total of 25 mutations in LGI1 associated with FLTLE have been 
identified (Nobile et al., 2009). 
LGI1 was initially described as a candidate tumour suppressor gene for glioma 
(Senechal et al., 2005), but more recently was identified as a subunit of the 
presynaptic Kv1 voltage gated potassium channel, preventing its inactivation (Schulte 
et al., 2006). LGI1 has been isolated from the brain where it serves as a ligand for 
two epilepsy-related receptors, ADAM22 and ADAM23 (Fukata et al., 2010). An 
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implication in epilepsy has been proved by loss of LGI1 in mice (LGI1 -/-), which 
causes lethal epilepsy. Interestingly, LGI1 has very recently been identified as an 
autoantigen, associated with limbic encephalitis/autoimmune synaptic 
encephalopathy (Lai et al., 2010), a condition often associated with seizures and 
neuropsychiatric symptoms. To address this issue in detail would, however, go 
beyond the scope of this thesis.   
 
Familial mesial temporal lobe epilepsy (FMTLE) 
A familial form of TLE with mesial seizure onset (FMTLE) was first recognised in twin 
studies by Berkovic et al (Berkovic et al., 1994; Berkovic et al., 1998), as a result of 
the observation of high concordance rates in monozygotic twins compared with 
dizygotic twins, and was reinforced by observations in non-twin families (Berkovic et 
al., 1996). 
Although there seems to be no clear cut consensus in the literature regarding sub-
classification of FMTLE, three subtypes are currently considered (Gambardella et al., 
2009): benign FMTLE without HS or FS, FMTLE associated with HS, and FMTLE 
associated with FS.  
 
Benign FMTLE without hippocampal sclerosis or febrile seizures  
Patients in this category of FMTLE typically present with early adulthood epilepsy 
onset, and with auras including psychiatric (predominantly déjà vu and jamais vu) 
and autonomic features (Berkovic et al., 1996). CPS and secondary generalisation 
are rare in this phenotype, and EEG recordings often do not show any epileptic 
activity. Patients have no signs of HS in MRI, and no history of childhood FS. The 
course of this TLE subtype is benign and the prognosis considered excellent, and 
therefore this condition is probably under-diagnosed. Despite the report of a probable 
linkage to chromosome 4q in a single pedigree (Hedera et al., 2007), the genetic 
basis of FMTLE is largely unknown. 
 
FMTLE associated with HS 
The identification of FMTLE associated with HS and/or FS, has altered the view that 
hippocampal sclerosis is exclusively associated with sporadic/ acquired forms of TLE. 
In 2003, Kobayashi et al. first described a relationship between FMTLE, HS and FS, 
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with large intrafamilial and interfamilial phenotypic heterogeneity with respect to 
severity of the epilepsy, history of FS, and presence of HS (Kobayashi et al., 2003).  
In 2/3 of families, the course is rather mild, while 1/3 present with severe, treatment-
refractory seizures. Approximately 10 % of patients have a history of FS, and the 
mean age of epilepsy onset is 10 years. Seizure semiology frequently includes CPS, 
with oro-alimentary automatisms, and, postictally, patients often are plagued by 
confusion. In accordance with benign FMTLE, secondary generalisation is rare. MRI 
reveals a broad variation in HS, from mild to severe, and the severity of hippocampal 
abnormalities have been reported to show a relationship with the clinical picture 
(Kobayashi et al., 2003).  
Interestingly, MRI findings of HS have also been observed in asymptomatic family 
members, which suggest that the HS itself might be inherited, rather than that the 
epilepsy leads to hippocampal alteration (Kobayashi et al., 2003). Histological studies 
of the HS in this subgroup of FMTLE patients have not shown any differences from 
sporadic MTLE. Taken together, these observations indicate that it is highly probable 
that at least some HS is based on a complex interaction between genetic and 
environmental factors. 
 
FMTLE associated with FS 
To date, reports have been published regarding two large FMTLE family clusters of 
FMTLE associated with FS (Baulac et al., 2001; Claes et al., 2004). The phenotype 
of the FMTLE in members of both families was characterised by onset before age of 
20 years, and none of the family members show signs of HS by MRI. The clinical 
course is benign, and, typically, the predominant clinical feature in members of these 
families is FS, while TLE occurs less often. Digenetic inheritance was proposed for 
one of the families, with gene loci on 18qter and 1q25-31 (Baulac et al., 2001), 
whereas in the second family linkage on 12q22-23.3 was shown (Claes et al., 2004). 
Other variants of FMTLE associated with FS have been demonstrated by 
identification of sodium channel mutations (SCN1A and SCN1B), which usually 
cause childhood febrile seizures, and rather infrequent MTLE and HS in a few family 
members (Scheffer et al., 2007; Colosimo et al. 2007).  
These should not be confused with the syndrome GEFS+, which is another epilepsy 
phenotype associated with sodium channel mutations, and is discussed later in this 
thesis.  
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It is important that this summary regarding our knowledge on familial forms of TLE, 
does not give the impression that TLE typically occurs in families. These familial 
syndromes account for only a fraction of TLE cases, and the TLE phenotype usually 
appears sporadically, without any indicators of inheritance. However, the growing list 
of family studies and increasing knowledge about the aetiology of complex diseases 
suggest that genetic factors are, indeed, involved in TLE and provide a good reason 
to move our focus away from the paradigm that TLE is merely an acquired disorder.  
TLE are complex disorders, in which a plethora of genes are probably involved, 
affected by environmental factors, and complicated further by post-transcriptional 
modifications. In order to learn more about the aetiology and pathogenesis of TLE, 
which is a prerequisite for establishing cures for patients, it is important both to 
broaden the spectrum of genetic tools used for investigation and, at the same time, 
dissect the sub-groups of the TLE, as based on phenotypic characteristics.  
Linkage analysis in large family pedigrees indicated autosomal dominant inheritance 
for the syndromes described above. However, as the majority of TLE cases, do not 
occur within families, linkage analysis has clear limitations. In this context, it should 
be noted that genetic variants may contribute to increased susceptibility to 
development of TLE. Identification of susceptibility genes can be performed by 
population-based association studies using candidate gene approaches. This has 
been one of the major tasks of this thesis, and is expounded in detail in subsequent 
sections. 
 
1.2.4 Genetic association studies in TLE  
Genetic changes may contribute to disease development in humans. On the one 
hand, rare mutations may occur that have extensive effects on the phenotype, 
typically leading to monogenic diseases. On the other hand, common genetic 
variants with limited phenotypic effects might also result in disease (Cordell et al., 
2005). A single nucleotide polymorphism (SNP) is a DNA sequence variation 
occurring when a single nucleotide (adenine, guanine, cytosine, or thymine) in the 
genome differs between members of the same biological species. These variations in 
the DNA sequence can affect the development of diseases.  
For a variation to be considered a SNP, it should occur in at least 1 % of the 
population. SNPs can occur in coding (gene) and non-coding regions of the genome.  
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As well as SNPs, other modifications in the genetic information may influence 
phenotype and confer disease susceptibility. These include rare variants with 
occurrence < 1% in the general population, copy number variations, and epigenetic 
modifications. The latter will be discussed later in more detail. 
Genetic association studies are designed to compare the frequency of specific alleles 
(in the narrow sense SNPs) in affected cases with those in unaffected control 
subjects. An allele is said to be associated with the disease when its frequency differs 
between cases and controls more than would be predicted by chance (Lander et al., 
1994). 
A large number of genetic association studies have been conducted on different 
epilepsy entities, candidate genes, and populations (Hirschhorn et al., 2002). Until 
recently, there was lack of systematic databases summarizing which candidate 
genes in which epilepsies have been investigated.  This gap has been filled by the 
establishment of an online repository of data relating to genetic association studies in 
epilepsies, the Epilepsy Genetic Association Database (http://www.epiGAD.org), 
which is supported by the ILAE Genetics Commission. To date, the database 
contains 212 susceptibility gene studies, of which approximately 25 % are related to 
TLE. The most important and most widely discussed susceptibility genes in TLE are 
summarised in table 1. 
 
 35 
 
Table 1: Summary of the most relevant genes tested for association with TLE 
Gene Number of studies 
(positive/negative) 
Allele Relevant studies Postulated function 
Interleukin- 6 (2/4) C511T - Kanemoto et al., 2000 
- Heils et al.,2000 
- Buono et al., 2001 
- Proinflammatory 
cytokine.  
- Interleukin 
receptors found in 
the hippocampus 
Prodynorphin 10 (4/6) L-allele  - Stögmann et al., 2002 
- Salzmann et al., 2008 
- Cavalleri et al. 2005 
- Opioid polypeptide 
hormone.  
- Involved with 
chemical signal 
transduction 
- Endogenous 
anticonvulsant? 
Apolipoprotein E  8 (3/5)  
 
- Briellmann et al., 2000 
- Cavalleri et al.,2005 
- Involved in 
catabolism of 
triglyceride-rich 
lipoprotein 
constituents 
GABA (B) 
receptors 
9 (2/7) G1465A - Gambardella et al., 
2003 
- Cavalleri et al., 2005 
- Metabotropic GABA 
receptors   
- hyperpolarizing 
neuron via opening 
of K+ channels 
Prion protein 
(PRNP) 
5 (2/3) N171S - Walz et al., 2003 
- Cavalleri et al., 2005 
- Express major prion 
protein 
- unknown function 
Negative association studies in italic font; source: Tan et al., 2004 and http://www.epiGAD.org 
 
1.2.5 Genome-wide association studies in TLE 
The first genome-wide association study (GWAS) in the epilepsies has only recently 
been published (Kasperaviciute et al., 2010). This large GWAS included 3445 
patients with partial epilepsies, of which 919 were diagnosed with mesial temporal 
lobe epilepsy. No significant genome-wide association was identified, leading to the 
conclusion that the genetic architecture of the partial epilepsies is likely to be highly 
complex. The consortium behind this study has suggested establishing further 
association studies, including GWAS, but in more homogenous and narrowly-defined 
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cohorts, with sample sizes that generate adequate power. This is challenging for 
several reasons, but particularly because population stratification may evolve when 
large samples are collected from different geographical regions.  
 
1.2.6 Genetic association studies carried out in this thesis 
Most genetic association studies involving TLE populations have not provided 
compelling results (Tan et al., 2004). One reason for this is that the TLE are 
genetically complex disorders, probably influenced by variation in several 
susceptibility genes. Another challenge is selection of appropriate candidate genes 
that have a high degree of biological plausibility. 
Many of the candidate genes investigated in epilepsies are those encoding neuronal 
ion channels or receptor proteins, based on the concept that alterations in these 
substrates may contribute to changes in membrane potential and lead to neuronal 
hyperexcitability. 
A rather newer concept is that altered glial function may also play an important role, 
and lead to hyperexcitability of neuronal tissue. Astrocytes, in particular have been 
suggested to promote epileptogenesis and disease progression in epilepsy and other 
neurological conditions (Binder and Steinhäuser, 2006; Seifert G et al., 2006, Eid et 
al., 2008). Further details on the concepts of glia mediated epileptogenesis are 
elaborated in section 1.3. This thesis describes 3 novel candidate genes investigated 
in 2 different association studies. The first association study (Paper II) focussed on 
the glial target genes AQP4 and KCNJ10, and the second study (Paper III) had  the 
extracellular matrix enzyme, matrix metalloproteinase-9 gene, MMP-9 as its subject.  
 
Genetic association study with AQP4 and KCNJ10 as candidate genes 
It has been recently demonstrated that ion homeostasis in the brain depends not only 
on proper ion channel function, but also on water transport, mediated by specific 
water channels. In particular, deletion of the glial water channel aquaporin-4 (AQP4) 
or its anchoring protein, alpha-syntrophin, interferes with K+ clearance from the 
extracellular space (ECS) after high frequency stimulation in slices or in vivo (Amiry-
Moghaddam et al., 2003; Binder and Steinhäuser, 2006), as well as after 
mechanically-induced spreading depression (Padmawar et al., 2005). The finding 
that AQP4 is co-localised with the inwardly rectifying K+ channel Kir4.1 (Nagelhus et 
al., 1999) led to the suggestion that AQP4 and Kir4.1 form a coupled water and K+ 
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transport unit (Amiry-Moghaddam et al., 2003; Nagelhus et al., 2004). The 
expression of this unit is compromised in TLE, as judged by the partial loss of AQP4 
and its anchoring complex from astrocyte endfoot membranes in the hippocampi of 
patients suffering from this condition (Eid et al., 2005). 
As deficiencies in K+ clearance would be expected to perturb neuronal excitability 
and increase the propensity to seizures, we investigated whether polymorphisms 
occur in those genes encoding AQP4 and the potassium channel Kir4.1 that are 
associated with TLE and its subgroups MTLE-HS and/or TLE-FS. To this end, we 
resequenced AQP4 to identify new SNPs in the TLE subgroups and also included 
known SNPs within AQP4 and KCNJ10 from HapMap (http://www.hapmap.org) and 
dbSNP (http://www.ncbi.nlm.nih.gov) databases.  
The timeliness of this study was underscored by previous data that suggest a 
possible association between variations in the human KCNJ10 gene and seizure 
susceptibility (Buono et al., 2004; Lenzen et al., 2005), and mutations in the KCNJ10 
gene, that are associated with the EAST/SeSAME syndrome, characterised by 
epilepsy (Bockenhauer et al., 2009; Scholl et al. 2009). 
 
Genetic association study with MMP-9 as candidate gene 
One elemental characteristic of the human brain is its capacity to undergo lifelong 
morphological and functional changes. These processes, also referred to as 
remodelling, include cortical reorganisation, synapse formation, and neurogenesis. 
Remodelling occurs during brain development and learning, but also serves as an 
adaptive mechanism to compensate for lost function (Bruel-Jungerman et al., 2007; 
Parent, 2007; Eisch et al., 2008). Studies of the hippocampus have identifed a 
relationship between synaptic remodelling and epilepsy. (Parent, 2007; Abrous et al., 
2005; Kempermann et al., 2004). In TLE, especially in cases with HS, remodelling 
may result in defective synaptic rearrangement of neuronal circuits and thus promote 
epileptogenesis and disease progression (Pitkanen and Lukasiuk, 2009).  
 A relatively recent discovery is the identification of matrix metalloproteinase-9 (MMP-
9) as a possible key factor in the development of aberrant synaptic plasticity and 
dendritic pruning in animal models of TLE (Wilczynski et al., 2008)  
MMP-9 is a member of the family of the matrix metalloproteinases (MMP), which 
constitute zinc-dependent extracellular or membrane-bound endopeptidases. Their 
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primary function is cleavage of extracellular matrix (ECM) proteins, and thus they are 
involved in processes of physiological tissue remodelling (Werb, 1997). 
MMP-9 has been implicated in various central nervous system (CNS) pathologies 
including stroke (Park et al., 2009), traumatic brain injury (Hayashi et al., 2009), 
cerebral arteriovenous malformations (Chen Y et al., 2008) influenza-associated 
encephalopathy (Ichiyama et al., 2007), systemic lupus erythematosus with CNS 
affection (Trysberg et al. 2004), and in meningitis, where it has been identified as a 
risk factor for developing neurological sequalae (Leppert et al., 2000).  
In addition, recent studies have indicated a physiological role for MMP-9 in neuronal 
plasticity, including learning and memory, as well as long-term-potentiation (Nagy O 
et al., 2006). It has been suggested that MMP-9 may have an initial detrimental 
effect, leading to neuronal cell loss, but also a subsequent beneficial (restorative or 
neuroprotective) effect (Zlokovic, 2006; Michaluk and Kaczmarek, 2007). 
Regarding a possible role in epileptogenesis, MMP-9 is believed to cleave 
extracellular matrix molecules in and around the synaptic cleft. Thus, MMP-9 
activation may be an essential step in the cascade of events leading to new synapse 
formation, and therefore could be critical for the sequence of events that underlies 
the development of seizures. 
Transgenic rats that over-express MMP-9 have been found to develop increased 
susceptibility to seizures, whilst deletion of the MMP-9 gene in mice leads to 
alleviation of seizures (Wilczynski et al., 2008). 
Based on these findings, we hypothesised that particular polymorphisms of the MMP-
9 gene could contribute to the development of TLE, or subgroups of this condition, 
notably MTLE-HS and TLE-FS. 
Despite a broad selection of SNPs in the MMP-9 gene and strong adherence to the 
general guidelines for establishing genetic association studies, we were unable to 
find any association with TLE or its subgroups. However, the possibility that TLE is 
associated with changes in MMP-9 expression or regulation could not be ruled out 
and should be the subjects of further research. 
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1.3 Alterations of glial cell function in temporal lobe epilepsy 
 
1.3.1 Glia – research milestones 
Glia cells (from glia, Greek for “glue”), also termed neuroglia or simply glia, are non-
neuronal cells and represent the most numerous cell type in the CNS. Glia was first 
described by the German doctor and pathologist Rudolf Ludwig Karl Virchow (1821 – 
1902), whom, contrary to the accepted dogma of the time, argued that the brain 
contains connective tissue. In a series of papers published in 1856 and his textbook 
(1858), Virchow introduced the term Nervenkitt, later translated to nerve-glue or glia 
(Virchow, 1862, Somjen, 1988). 
Glial cells are subdivided into three main groups: Oligodendroglia, which are involved 
in the production of myelin and “insulation” of nerve cell axons; microglia, which are 
part of the CNS immune system; and astroglia or astrocytes, which were thus named 
due to their characteristic star shape by the Spanish neuroscientist and pathologist, 
	
			– 1934).  
For decades astrocytes have been considered as relatively passive cells, the 
existence of which was mainly justified by their role as “servants to neurons”. They 
were considered to have three functions: i) to act simply as glue holding nerve cells in 
place, ii) to be involved in scar formation in the CNS, and iii) to have a nutritive 
function in relation to neurons. They were regarded as electronically silent and 
deficient in ion channels and transmitter receptors. 
In recent years, this view has altered radically. We have learned that astrocytes form 
an intimately connected network with neurons, and serve as active communication 
elements with a large variation of integrative functions in the CNS. Knowledge about 
astrocytes is crucial for understanding normal brain functioning, and astrocytes 
provide a promising new area for treatment of neurological diseases, including 
epilepsy. 
Before elaborating further on astrocyte function and dysfunction, it is important to 
note that astrocytes are not one single cell type. Quite the contrary, different cells 
with astroglial properties exist both intermingled in a given brain region, and, with 
varying distribution, in different brain areas. To date, classification into two main 
astrocyte cell types has been established. These are termed GluT cells and GluR 
cells, based on their segregated expression of glutamate transporters (GluT cells) 
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and ionotropic glutamate receptors (GluR cells), respectively. These astrocyte 
subtypes have dissimilar electrophysiological and anatomical properties, and show 
diverse immunoreactivity to different markers (Jabs R et al., 2008). Although both cell 
types are referred to as astrocytes, their functional impacts should be considered to 
differ. However, which separate tasks the respective astrocyte subtypes perform is 
incompletely understood.  
Astrocytes express a large range of ion channels and receptors, comparable with 
those from neurons (Verkhratsky and Steinhäuser, 2000; Seifert et al., 2004). 
However, the “quality and quantity” of receptors and channels varies between 
neurons and astrocytes. Neurons, for example, show a strong expression of Na+ 
channels and a relatively weak expression of K+ channels, while in astrocytes, K+ 
channels greatly predominate. 
One of these channels is Kir4.1, which belongs to the family of inwardly rectifying 
potassium channels.  Kir.4.1 is co-localised with the astrocyte water channel AQP4 in 
glial cells (Nagelhus et al., 1999) and it has been suggested that AQP4 and Kir4.1 
channels work in concert to  maintain K+ and water homeostasis in the CNS 
(Nagelhus et al., 1999; Nagelhus et al., 2004, Soe et al., 2009). Notably, deletion or 
mislocalization of AQP4 delays K+ clearance from activated synapses and increases 
severity of seizures (Amiry-Moghaddam et al., 2003; Binder et al., 2006).  As these 
channels are a major focus of this thesis, their roles in epilepsy are discussed in 
more details in subsequent sections.  
In contrast with mature neurons, astrocytes are usually coupled in networks of gap 
junctions, mainly formed by connexins 30 and 43, through which astrocytes can 
“communicate” with each other and dissipate molecules like K+ and glutamate (Theis 
et al., 2005). Deletion of these connexins delays K+ clearance from activated 
synapses (Walraff et al., 2006). Gap junctions also contribute to the transmission of 
intercellular Ca2+ waves in astrocytes, which may be important for release of 
transmitters such as glutamate. 
A further crucial function of astrocytes is the clearance of transmitters released by 
active neurons. Astrocytes express glutamate transporters (EAAT1 and EAAT2; in 
rodents termed GLAST and GLT-1), which take up glutamate from the ECS, and thus 
prevent glutamate accumulation that might otherwise lead to excitation and/or 
excitotoxicity (Bergles et al., 1999; Danbolt et al., 2001). 
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Another feature of astrocytes, which is still somewhat controversial, is the property 
that is currently subsumed in the concept of “gliotransmission”. Gliotransmission is 
the ability of astrocytes to release chemical transmitters, including glutamate and 
ATP. This ability was first described in a classical study by Parpura and colleagues in 
1994, in which glutamate release from astrocytes was demonstrated in astrocyte-
neuron co-cultures (Parpura et al., 1994; Volterra and Meldolesi, 2005).  Following 
this groundbreaking study, a series of further studies demonstrated that 
gliotransmitter release is probably dependent on an increase in intracellular Ca2+ 
concentrations in astrocytes. The release was proposed to be orchesterated by G-
protein coupled neurotransmitter receptors, which, via phosphorylase C, effect 
release of Ca2+ from internal stores in astrocytes (Haydon, 2001). Indeed, this 
proposal has been strongly supported by several studies that have shown that 
stimulation of neuronal afferents induces an elevation in Ca2+ concentrations within 
astrocytes (Porter et al., 1996), which then can spread to adjacent astrocytes 
(Charles et al., 1991). This means that astrocytes comprise a chemical form of 
excitability that is linked to neuronal activity in a bidirectional fashion (Haydon, 2001). 
Calcium-dependent transmitter release is a mechanism that, until recently, was 
considered to be only available to neurons. 
It is still unclear which functions are involved in these astrocyte mechanisms, but it 
does seem certain that astrocytes have the ability to influence and modulate 
neuronal activity (Angulo et al., 2004). On the basis of these various interactions and 
effects associated with astrocytes, it seems plausible that altered astrocyte function 
may contribute to disease development and progression in different neurological 
diseases, including epilepsy. 
 
1.3.2 Astrocytes and epilepsy 
Current antiepileptic treatment concepts are mainly based on the principle that 
epileptic seizures arise from abnormal excessive or synchronous neuronal activity in 
the brain (Rogawski et al., 2004). Phenobarbital, for example, is an effective GABA 
receptor agonist that increases the efficacy of inhibitory synapses. Another example 
is phenytoin, a sodium channel blocker that reduces the rate and/or amplitude of 
action potentials in neurons, and hence inhibits high-frequency neuronal firing. 
Valproate attenuates excitability via a combination of several mechanisms, as 
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reviewed in (Johnston, 1984; Löscher, 1993), all of which are believed to have an 
impact on neuronal functions alone. 
While 2/3 of all epilepsy patients respond successfully to currently available AEDs, 
the remaining 1/3 continue to suffer recurrent seizures, despite per se optimised 
pharmacological treatments (Kwan and Brodie, 2000). These pharmacoresistant 
cases are mainly represented by patients suffering from TLE. In order to fulfil the 
unmet medical needs of patients with pharmacoresistant TLE, alternative 
pharmacological treatment strategies should be a goal of epilepsy researchers and 
epileptologists. During recent years, evidence has accumulated that indicates that 
proper neuronal function is not possible without glial cells. Glial cells, especially 
astrocytes, are critically involved in the maintenance of homeostasis for ions and 
water, and hence in the pathophysiological mechanisms that lead to neuronal 
hyperexcitability and epilepsy. This makes glial cells an exciting subject for novel 
treatment concepts in epilepsy, especially for pharmacoresistant TLE (Jabs et al., 
2008). 
The hippocampal seizure focus in TLE has been the subject of most studies on the 
aetiology and pathogenesis of the epilepsies. The rationale for this is the need for 
novel treatment strategies for patients with TLE due to high pharmacoresistance. In 
addition, the availability of tissue from surgically-treated TLE patients and the wealth 
of experience on use of animal models of TLE are further reasons for extensive 
research in this field.  
 
1.3.3 Roles of the inwardly rectifying potassium channel Kir4.1 
Glial cells are characterised by strongly negative resting membrane potentials and 
highly selective membrane permeability to potassium ions (K+) (Kuffler et al., 1966).  
These fundamental properties are maintained by profuse expression of K+ channels, 
of which inwardly rectifying K+ (Kir) channels predominate. Kir channels are 
responsible for the main K+ conductance and sustain the resting membrane potential 
of glial cells close to the equilibrium potential of potassium, as demonstrated by a 
variety of electrophysiological studies (Sontheimer et al., 1994; Verkhratsky and 
Steinhäuser, 2000).  
In contrast with the vast majority of K+ channels, Kir channels are characterised by 
their ability to conduct more efficiently inwards than outwards. They are reliant on the 
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outward K+ concentration [K+]out  and are modulated by intracellular factors and 
secondary messengers (Doupnik et al., 1995). 
The Kir channel family is generally divided into seven subfamilies (Kir1.0 - Kir7.0), 
with a total of between 16 and 20 members (Nichols et al., 1997; Olsen and 
Sontheimer, 2008). 
Kir channels form tetrameric structures, assembled from homomeric or heteromeric 
Kir subunits, which implies further functional diversity (Krapivinsky et al., 1995). 
Based on different biophysical properties, Kir channels segregate into different 
subtypes (Butt et al., 2006). Glial cells may express all subtypes of Kir channels. 
However, the most abundant Kir channel in glial cells, and functionally the most 
important by far, is Kir4.1, which belongs to the subtype of ATP-dependent Kir 
channels. 
Kir4.1 has been detected in astrocytes, oligodendrocytes, cerebellar Bergmann glia 
cells, and retinal Müller cells (Takumi et al., 1995; Ishii et al., 1997; Schroder et al., 
2000; Kalsi et al., 2004). 
As early as 1980 the idea was proposed that K+ could be redistributed by Kir 
channels along the membrane of a single cell, or a network of cells connected via 
gap junctions from a region with high [K+] to a region with lower [K+] (Orkand et al., 
1980). This spatial buffering hypothesis was strengthened by the finding that Kir4.1 
expression varies within a given brain region. In fact, Kir4.1 shows distinct subcellular 
localisation, consistent with a specific role in transport of K+ by glia between neurons 
and blood vessels. Kir4.1 is predominantly localised at distant astrocyte processes 
surrounding synapses or blood vessels (Nagelhus et al., 1999, Higashi et al., 2001). 
This polar distribution of Kir4.1 strengthens the hypothesis that potassium released 
by active neurons, is taken up into the astroglial syncytium and then distributed to 
blood vessels at the glia-vascular interface, as illustrated in figure 3. 
 
K+ buffering is a fundamental property of normal brain functioning. All neuronal 
activity, strictly every single action potential, leads to release of K+ from neuronal 
tissue into the ECS. Without a rapid and effective buffering mechanism, any increase 
in extracellular K+ concentration could compromise neuronal firing and normal brain 
functioning.  
Lack of Kir4.1 channels will result in depolarization of glia, increased excitability and 
propensity to seizures (Kofuji et al., 2000; Djukic et al., 2007), as shown in Kir4.1 -/- 
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mice. Interestingly, not only is K+ buffering markedly impaired in these mice (Chever 
et al., 2010; Haj-Yasein et al., in press), but also uptake of the excitatory 
neurotransmitter glutamate (Djukic B, 2007). Glutamate is most effectively taken up 
by astrocytes at negative resting potentials. Hence, impaired expression of Kir4.1 
leads to reduced glutamate uptake and increased propensity to seizures.  
 
Even subtle changes in Kir4.1 function could result in defective regulation of [K+] and 
thus present an attractive mechanistic hypothesis for an association between genetic 
variation and seizure susceptibility. Recent genetic studies have indicated an 
association between missense variations in the gene encoding Kir4.1, KCNJ10, and 
seizure susceptibility in both mice and humans (Buono et al., 2004; Ferraro et al., 
2004). Bouno et al. detected a non-synonymous SNP (rs1130183) in the human 
KCNJ10 gene (Arg271Cys) that was associated with seizure resistance in groups of 
patients with either focal or generalised epilepsy (Buono et al., 2004). In addition, the 
recent identification of a syndrome characterised by epilepsy caused by mutations in 
KCNJ10, emphasises the importance of Kir4.1 in cerebral [K+] regulation and the 
potential for KCNJ10 as a seizure-susceptibility gene (Bockenhauer et al., 2009; 
Scholl et al. 2009). 
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Figure 3: Presumed mechanism of potassium spatial buffering by the astrocyte membrane 
channel Kir4.1. 
A: Potassium efflux from synaptic terminal during neuronal activity; B: Uptake of potassium by 
astrocyte Kir4.1 channels and possibly a concomitant water influx via water channel AQP4 to dissipate 
imbalance of ion concentration; C: Potassium is spatially redistributed by buffer currents and 
preferentially released to the perivascular space due to clustering of Kir4.1 channels in astrocyte 
endfeet.  D: Defective Kir4.1 and/or AQP4 leads to increased extracellular potassium concentration 
and depolarisation of neuronal tissue. Perturbed K+ clearance may play a role in epileptogenesis. 
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1.3.4 Roles of the water channel aquaporin-4 
Water homeostasis is a fundamental property of all living organisms. Thus, the 
mechanisms of how water passes cell membranes are of fundamental interest. For 
about 200 years, diffusion, first recognised by the French physiologist René Joachim 
Henri Dutrochet (1776-1847), was believed (albeit debated) to be the basic way by 
which water passed through the lipid bilayer of plasma membranes. This view was 
revolutionised by the detection of specific transmembrane water channels, later 
named aquaporins, in 1991 (Preston and Agre, 1991). For this discovery, Peter Agre 
was awarded the Nobel Prize in Chemistry in 2003. As with diffusion, the transport of 
water through aquaporins is energy-independent and driven by an osmotic gradient 
across the plasma membrane. However, the velocity of water flux through aquaporins 
greatly exceeds that of diffusion. To date, 13 mammalian members of the aquaporin 
family have been characterised, with localisation in different organs. In the CNS, 3 
water channels have been detected, AQP1, AQP4, and AQP9. Aquaporin 1 is 
expressed in the epithelium of the choroid plexus and is most probably relevant for 
cerebrospinal fluid (CSF) secretion (Nielsen et al., 1993). Aquaporin 9 is permeable 
not only to water, but also to a range of other molecules. AQP9 is expressed in 
tanocytes of the third ventricle ependyma, and also in astrocytes and neurons. AQP9 
may be involved in brain energy metabolism, but its exact role is still unclear (Badaut 
et al., 2004). The role of aquaporin-4 (AQP4) has been studied in most detail and is 
also of principal interest in the context of this thesis. 
AQP4 mRNA was originally detected in brain by Jung et al. in 1994 (Jung et al., 
1994), and the protein was later shown to be expressed in astrocytes, with a polar 
distribution in perivascular endfeet and in the glia limitans towards the pial surface 
(Nielsen et al. 1997; Amiry-Moghaddam, 2004), figure 4. This distribution, with the 
highest density towards the brain-liquid interfaces, implies an important role in water 
homeostasis in the brain.  
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Figure 4: Distribution of AQP4 in the astrocyte membrane in the brain.  
AQP4 is strongly enhanced in the astrocyte membrane towards the basal lamina surrounding blood 
vessels and towards the pial surface. Arrows indicate hypothetic water flux via AQP4 (Amiry-
Moghaddam, 2004). 
 
AQP4 regulates brain oedema formation and resolution in a range of neurological 
conditions, such as stroke, glioblastoma multiforme, brain abscesses, and 
hydrocephalus (Manley et al., 2000; Amiry-Moghaddam et al., 2003; Bloch et al., 
2005; Papadopoulos and Verkman, 2005). AQP4 has also been implicated in K+ 
clearance, neuronal excitability and epilepsy (Eid et al., 2005; Binder et al., 2006), 
but its precise roles in brain are still elusive. It has been shown that the ECS shrinks 
significantly during neuronal depolarisarion (Dietzel et al., 1982). Shrinkage of the 
ECS could occur via AQP4 mediated water transport into perisynaptic astrocyte 
processes. The observation that the ECS at the same time increases in the neuropil 
distant to active synapses (Niermann et al., 2001), led to the theory that perisynaptic 
uptake of water is followed by efflux of water at a distant astrocyte membrane 
compartment. 
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1.3.5 Functional association between Kir4.1 and AQP4 
AQP4 and Kir4.1 have entirely distinct functions, in as much as they selectively 
transport water and K+, respectively. However, based on the close spatial relationship 
between these proteins in glial membrane domains, it was suggested that there is an 
obligatory coupling between water transport and K+ clearance in the CNS (Nagelhus 
et al., 1999). In support of this hypothesis, high frequency stimulation of thalamic 
afferents to layer IV in acute cortical slices induces water fluxes to the superficial 
cortical layers, along with K+, as recorded by K+-sensitive microelectrodes (Niermann 
et al., 2001). Testifying to the interdependence of these transport processes, deletion 
of AQP4 (Binder et al., 2006) or elimination of the endfoot pool of this water channel 
(Amiry-Moghaddam et al., 2003) delays K+ clearance and increases the severity of 
seizures  The functional relationship between AQP4 and Kir4.1 is, however, debated. 
Verkman’s group failed to show altered Kir4.1 channel function in AQP4 deficient 
mice (Zhang and Verkman, 2008). On the contrary, Soe et al reported that Kir4.1 
channels are sensitive to cell volume changes and thus dependent on AQP4 (Soe et 
al., 2009). Moreover, a functional and molecular interaction between AQP4 and the 
Na+/K+ATPase (Illarionova et al., 2010) could also underly the effects of AQP4 
deletion/mislocalization on extracellular K+ kinetics.  Recently, AQP4 deletion was 
shown to delay recovery of extracellular K+ in the hippocampal stratum pyramidale, 
whereas K+ flux to stratum radiatum was enhanced (Strohschein et al., 2011). 
Impaired K+ uptake by the Na+/K+ATPase and facilitated K+ buffering by increased 
gap junctional coupling, were suggested to account for these opposite effects on K+ 
dynamics.     
Studies in humans support the idea that certain forms of epilepsy are linked to 
perturbations in water and K+ homeostasis. Most notably, the K+ buffering capacity in 
MTLE-HS hippocampi is reduced in comparison with non-MTLE-HS hippocampi 
(Bordey and Sontheimer, 1998). This change is most pronounced in the CA1 region, 
where patch clamp experiments have demonstrated impaired uptake of K+ into 
astrocytes through inwardly rectifying K+ channels (Hinterkeuser et al., 2000). In 
addition to altered potassium ion kinetics, there is strong evidence that water 
accumulates in sclerotic hippocampi, as shown in MRI and in diffusion-weighted 
imaging of patients with MTLE-HS (Hugg et al., 1999). These functional changes 
mesh nicely with the finding that patients with MTLE-HS display a partial loss of 
AQP4 from astrocyte endfoot membranes (Eid et al., 2005). 
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1.3.6 The dystrophin-associated protein complex (DAPC) - an anchoring site for 
Kir4.1 and AQP4? 
Dystrophin is a rod-shaped cytoplasmic protein and a vital part of a large protein 
complex, the dystrophin-associated protein complex (DAPC). The DAPC includes 
dystrophin and a number of dystrophin-associated proteins, which together connect 
the cytoskeleton to the surrounding extracellular matrix through the cell membrane. 
The dystrophin gene, with locus Xp21, has a length of 2.4 megabases and is the 
largest gene of the human genome. Mutations in the dystrophin gene are associated 
with neurological diseases, such as Duchenne and Becker muscular dystrophies. 
The dystrophin gene transcribes various isoforms (i.e., proteins of varying lengths 
containing different segments of the basic dystrophin sequence, which are encoded 
by different mRNAs, generated mainly by unique, tissue-specific promoters, but also 
by alternative splicing or use of different polyA-addition signals). The full length 
isoform of dystrophin is Dp427 (427 kDa), which is found mainly in skeletal muscle. In 
the brain, the predominant isoform is Dp71, which is expressed in astrocytes 
(Lederfein et al., 1992). 
Altered DAPC has recently been implicated in animal models of status epilepticus 
(SE), indicating that dysfunction of dystrophin induced by SE may result in 
endothelial and astroglial damage, with breakdown of the blood-brain barrier (BBB) 
and increased vascular permeability as part of the pathogenesis of epilepsy (Sheen 
et al., 2010). Moreover, epilepsy is reported to occur at a higher incidence in patients 
with Duchenne and Becker muscular dystrophies (Goodwin et al., 1997; Tsao et al., 
2006). This could indicate that alterations in the DAPC may lead to an increased 
propensity to seizures.  
Nevertheless, little is known about the role of the DAPC/dystrophin-glycoprotein 
complex (DGC) in the human CNS physiology and pathophysiology, or the epileptic 
brain. Altered anchoring via DAPC may cause lack of Kir4.1 and also other important 
channels, such as the brain water channel, aquaporin-4 (AQP4), and thus critical for 
epilepsy development. 
 
There is accumulating evidence that both AQP4 and Kir4.1 are anchored to the 
DAPC, supporting their co-active function in water and potassium homeostasis in the 
brain. This theory was originally generated by results obtained from double 
immunogold labelling in retinal Müller cell membranes that revealed co-enrichment of 
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Kir4.1 and AQP4 in vitreal and perivascular endfeet membranes (Nagelhus et al, 
1999). Their close vicinity strengthens the theory that both channels are attached to 
the DAPC. Both channels are arranged in a polar distribution, with highest density in 
astrocyte perivascular endfeet and in astrocyte processes that form the glia limitans. 
Further evidence for DAPC association with AQP4 comes from strains of mice that 
lack dystrophin (mdx mice), which display strongly reduced perivascular AQP4 
expression (Liu et al., 1999; Nico et al. 2003).  
 
Kir4.1 is localised in glial cells by its association with the DAPC through a PDZ 
domain-mediated interaction, as shown in immunoprecipitation experiments in mouse 
brain as well as in cultured cortical astrocytes (Connors et al., 2004), see figure 4. 
Further support for a functional interaction between AQP4 and Kir4.1 has been 
obtained from studies on alpha-syntrophin -/- mice, which display serious mislocation 
of AQP4 and also delayed K+ clearance, despite unchanged expression of Kir4.1 
(Amiry-Mogghadam et al., 2003). Furthermore, it has been shown that KO of 
dystrophin 71, another member of the DAPC, results in decreased AQP4 and Kir4.1 
expression (Dalloz et al., 2003).  
Taken together, these data suggest an anatomical and functional entity between 
AQP4 and Kir4.1. 
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Figure 5: Diagram showing the presumed molecular basis for anchoring of AQP4 and Kir4.1 in 
the perivascular and subpial astrocyte membrane.  
The dystrophin complex is anchored to the basal lamina via laminin and agrin and is presumed to bind 
AQP4 and Kir4.1 by way of alpha-syntrophin or other syntrophins. Other molecules involved in 
anchoring are the PDZ binding domain and beta-dystroglycan. H1 indicates the coiled-coil motif 
interaction between Dp71 (the major dystrophin isoform in brain) and alpha-dystrobrevin (Amiry-
Moghaddam et al., 2004).  
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2.  Material and methods 
 
2.1 Phenotype studies on a Norwegian TLE population 
 
2.1.1 Study population and data assembly 
The original collection of patient data was carried out between 2000 and 2004 at 
seven tertiary Norwegian Medical Centres in a cooperative project (GenEpa), and 
was initially supported by GlaxoSmithKline. Hospitals involved in data assembly 
were the former Rikshospitalet University Hospital and the former Ullevål University 
Hospital, since merged to Oslo University Hospital; the former National Centre for 
Epilepsy, Sandvika; St Olav University Hospital, Trondheim; Haukeland University 
Hospital, Bergen; and Akershus University Hospital, Lørenskog. The aim of the 
initiative was to accrue a large dataset of Caucasian epilepsy cases and ethnically-
matched controls, and to associate DNA sequence allelic variations in candidate 
genes with epilepsy phenotypes. After discontinuation of the GenEpA initiative an 
agreement was made between GSK and the principal investigator of the Norwegian 
GenEpa group, Professor Leif Gjerstad, which enabled handling of the GenEpA 
raw data within the framework of this thesis.  
In total, 218 patients with TLE (according to the ILAE criteria, classification 1989) 
were included in the study. Inclusion criteria for all individuals were: age > 18 years; 
Caucasian race, with at least three of four grandparents of Scandinavian origin. The 
controls had no known familial relation to the TLE patients (typically spouse or 
partner). Standardised evaluation forms were used for all TLE patients and 
controls.MRI (typically 1 or 1.5 T, with sagittal and axial T1, axial and coronal T2, and 
Fluid-Attenuated Inversion Recovery (FLAIR) was performed in all 218 patients in 
order to differentiate cases with hippocampal sclerosis (MTLE-HS) from the 
remainder of the TLE patients (including patients with neocortical TLE and MTLE 
patients without HS). We identified 56 patients with MTLE-HS and 162 cases with 
other TLE. 102 patients had a history of febrile seizures, while 105 did not report any 
febrile convulsions in childhood. For 7 patients febrile seizure status was 
inconclusive.  
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2.1.2 Explorative study variables – phenotype factors 
Patient groups were compared with respect to seizure semiology, age at epilepsy 
onset, appearance of FS in the patients and in first-grade family members, 
comorbidity with psychiatric and somatic diseases, and years of formal education. 
Demographic data (including ethnic background of 4 grandparents) were evaluated in 
all patients and controls. General medical history, including former and present 
antiepileptic medication, with duration of use and efficacy, were assembled. 
Diagnostic criteria for TLE, as described by the ILAE, were adhered to when 
establishing the diagnosis (epilepsy onset, seizure semiology, seizure type and 
frequency, etc., see also http://www.ILAE.org). Patient histories of febrile seizures 
were obtained from medical records and anamnesis. Family histories of epilepsy 
and/or febrile seizures were collated. Neurological examinations were performed on 
all patients. Data from EEG, performed at any time, and MRI, performed within 5 
years of study enrolment, were collected. Within both case and control subjects, 
additional phenotypic factors were measured, such as height, weight, and waist 
circumference. A short questionnaire on general medical history, mood disorders, 
and educational status was completed for all participants. 
 
2.1.3 Statistical analysis of phenotype data 
The two clinical/ epidemiological investigations performed as part of this thesis, were 
studies on different subgroups of patients in a mixed TLE population. In the broadest 
sense, both studies could be classified as pilot studies. To our knowledge, few, if any, 
studies on mixed cohorts of operated and non-operated TLE patients have been 
previously performed. In the first study (paper I), data were described by proportions 
and medians with ranges. Crude associations between variables were investigated 
using chi-square tests or Fisher’s exact tests (when number of observations was too 
small for one or both variables). Due to the “pilot character” of the study, we did not 
correct for multiple testing.  
In our second study, we tested whether a certain group of patients, TLE-FS, could be 
segregated from other TLEs. This is the first study that has systematically evaluated 
this patient group. This study should also be regarded as a pilot study, and therefore 
we did not adjust for multiple testing. Categorical variables were described by 
proportions and continuous variables by medians and ranges. Associations between 
variables were studied using chi-square tests or Fisher's exact tests. Crude 
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associations between the two patient subgroups and age of epilepsy onset were 
assessed using the Cochran–Armitage test for trend. To correct for possible 
confounding, caused by overrepresentation of MTLE-HS in TLE-FS, multiple logistic 
regression models were adjusted for MTLE-HS and the results expressed as odds 
ratios (OR) with 95 % confidence intervals (CI). P-values < 0.05 were considered 
statistically significant. Given the relatively large sample size, we were able to fit 
multivariate models and adjust for possible confounders in addition to simple 
univariate analyses (chi-square tests). However, most of our results are highly 
statistically significant even when compared at a stricter significance level of 1 % (i.e., 
p < 0.01). 
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2.2 Genetic association studies in a Norwegian TLE population 
2.2.1 Study population and data assembly 
The study population and data assembly for genetic studies are identical to those for 
the phenotype studies, as described in section 2.1.1. 
 
2.2.2 Explorative study variables - genotype factors 
Allelic sequence variations in candidate genes were investigated by genetic 
association studies, as summarised in table 2. 
 
Table 2: Candidate genes chosen for genetic association studies 
Candidate 
gene 
 
Gene product 
 
Locus Length in 
bp 
SNP detection 
AQP4 Water channel 
aquaporin-4 
 
18q11.2-
q12.1  
13,706  Comprehensive search for DNA 
variation was conducted by PCR. 
Resequencing of the 22 
overlapping PCR amplicons, 
covering the whole AQP4 gene, 
revealed 51 putative SNPs.  
 
KCNJ10 Inwardly rectifying 
potassium channel, 
Kir4.1 
 
1q23.2 32,854  43 SNPs from KCNJ10 were 
chosen from HapMap 
(www.hapmap.org) and dbSNP 
(www.ncbi.nlm.nih.gov/SNP) 
 
MMP-9 Extracellular enzyme 
matrix 
metalloproteinase-9 
 
20q11.2-
q13.1 
7,536 40 SNP from the MMP-9 gene 
were used in the assay design. The 
SNPs were chosen from HapMap 
(www.hapmap.org) and dbSNP 
(www.ncbi.nlm.nih.gov/SNP) 
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2.2.3 Case-control constellations tested for association 
The following case-control constellations were tested in all association studies 
performed in this thesis:  
a)  Temporal lobe epilepsy (TLE) versus healthy control subjects 
b)  Mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS) versus 
healthy control subjects 
c) MTLE-HS versus other TLE (without MTLE-HS) 
d)  TLE with a history of febrile seizures versus healthy control subjects 
e)  TLE with a history of febrile seizures versus TLE without a history of febrile 
seizures 
 
 
2.2.4 Validation and characterisation of SNPs 
SNP genotyping on all cases and controls was performed using the MassARRAY 
system from Sequenom, www.sequenom.com (San Diego, USA). All SNPs with a 
known allele frequency in Caucasian populations were included in the initial primer 
design. Genotypes were assigned in real-time (Tang et al., 1999) by using the 
MassARRAY SpectroTYPER RT v3.4 software (Sequenom) based on the mass 
peaks present. All results were manually inspected, using the MassARRAY 
TyperAnalyzer v3.3 software (Sequenom). 
 
2.2.5 Statistical data analyses 
Analysis of single SNPs and haplotypes in cases versus control groups 
HaploView 4.0 software package (Barrett et al., 2005) was used for defining 
haplotype blocks and for investigating possible associations between single SNPs 
and haplotypes within blocks. The criterion for block definition was that suggested by 
Gabriel et al., 2002. Both nominal p-values and p-values corrected for multiple testing 
were considered. The boundary used for indicating significance was set to 5 % for 
the single SNPs and haplotypes. Multiple corrections of the p-values were 
determined by repeating 10,000 random permutations of the case/control status. 
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Explorative data analysis 
Prior to the modelling, allele combinations (AA, AB, BB) for each SNP were recoded 
into 0–1 dummy predictor variables (one dummy predictor for each allele present in 
the SNP). 
 
Multivariate data analysis for SNP selection 
Together with a categorical response variable (indicating the case/control status of 
each subject in the dataset), the dummy predictors were included in a multivariate 
variable selection approach based on Partial least squares (PLS) methodology 
(Westerhuis et al., 1998; Nocairi et al., 2005). The PLS methodology is useful for 
establishing low dimensional subspaces of predictors in regression and classification 
problems and prevents overfitted models in situations where the number of predictors 
islarge in comparison with the number of subjects investigated. In order to assure 
additional sparseness (avoiding models influenced by unimportant SNPs), we used 
the Powered PLS (Indahl, 2005) in combination with the jackknife approach (Martens 
and Martens, 2001). Full (leave-one-out) cross validation was used to estimate the 
appropriate subspace dimension, as well as the importance of the individual SNPs. In 
order to minimise the number of SNPs required for prediction of case/control status, 
the candidate SNPs found to be most significant by combining the Powered PLS and 
jackknife approaches were re-investigated by linear discriminant analysis (LDA) 
(Hastie et al., 2001). LDA is a well-established statistical approach for solving 
classification problems. A group centre (prototype subject) is estimated for each 
group (here we have considered two groups, subjects and controls). Classification of 
a subject is obtained by assigning it to the group corresponding to the closest group 
centre according to a metric that is estimated as common within the group’s 
covariance structure. 
 
Predictive modelling and significance 
The precision (associative strength) of the LDA-model defining the appropriate 
covariance metric from the final set of selected SNPs was measured as the 
percentage of correctly classified individuals computed by full cross validation. The 
boundary used for indicating model significance was set to 5 % (corrected for multiple 
testing of models). The significance numbers were estimated by 10,000 random 
permutations of the case/control status. 
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2.2.6 Probing non-coding SNPs for potential function 
It is generally hypothesised that many disease-associated sequence variants in non-
coding regions could influence the phenotype by altering gene regulation. In this 
respect, it is common to use evolutionary conservation as a guide for indicating non-
coding regions with potential biological function (McCauley et al., 2007). Thus, for 
TLE-associated non-coding SNPs, we manually inspected the level of sequence 
conservation at their genomic locations using multiz28way alignments provided by 
the UCSC genome browser (Bejerano et al., 2005; Karolchik et al., 2008). 
Specifically, we looked for short (minimum 5nt) and conserved [all bases identical at 
the orthologous sites in monkey (rheMac2), mouse (mm8), dog (canFam2), and 
opossum (monDom5)] motifs that covered the SNP position. In addition to sequence 
conservation, we analysed whether any of the TLE-associated SNPs overlapped with 
known transcriptional enhancers (a genomic data track, provided by the UCSC 
genome browser). 
 
2.2.7 Critical consideration of patient selection, data assessment, and 
interpretation 
 
Phenotype definition problems and selection bias 
Phenotype definition is a principal challenge in complex diseases like the epilepsies, 
and should always be an important concern in the early planning and design of any 
genetic association study. The specificity of the phenotype should be as high as 
possible. However, this task seems to pose particular difficulties, especially in the 
epilepsies, due to the sometimes subtle clinical presentation. The common clinical 
feature in epilepsies is the seizure, a mostly transient event, often never observed by 
the physician, and sometimes not observable at all. In these cases, diagnosis has to 
be established on other, indirect features, such as age at onset, seizure frequency, 
comorbidity, EEG findings, MRI results etc. From the opposite perspective, the same 
underlying disease entity may present a large variety of different types of seizures; 
the seizure itself usually does not always provide any further information about the 
aetiology and pathogenesis of the disease. 
Another major issue for most genetic association studies is recruitment of a large 
number of subjects, which often requires collaboration between centres from different 
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geographical regions. This may lead to population stratification, due to mixing of 
genetically disparate subjects.  
Another problem may arise from dissimilar routines in diagnostics and in data 
ascertainment.  
 
In the studies described in this thesis, patients were recruited from seven different 
Norwegian hospitals, which may have affected phenotype specificity and could have 
introduced heterogeneity into the data. In this respect, it may be advantageous that 
most centres involved in subject selection are classified as tertiary centres, which 
implies a high level of competence in reaching a diagnosis and in phenotype 
selection. However, patients attending those facilities are often pre-selected, as they 
usually represent the most medicament-refractory and severe cases.  
Every subject included in the studies described, had to be diagnosed according to 
highly rigid standards that were applied to ensure consistency and narrowness in 
phenotype definition. Cases in our study were chosen as specified in the 1989 ILAE 
classification (Proposal for revised classification of epilepsies and epileptic 
syndromes, 1989).  
 
Population stratification and genetic heterogeneity 
Population stratification 
Population stratification is defined as the presence of a systematic difference in allele 
frequencies between sub-populations within a population due to different ancestry.  
One major pitfall of genetic association studies is that population descriptions are 
sometimes vague. When exploring a set of genetic association studies, a large 
variety of population descriptions can be found. These range from use of racial group 
designations, to national labels, to geographic descriptors. Unclear assignment as 
non-random group sampling provides further confusion. These methodological 
failures often lead to population stratification, and result in replication attempts being 
almost impossible. Thus, there has been increasing focus on the use of a precise 
population description in genetic association studies (Kaplan et al., 2003; Fullerton et 
al., 2010).  
Populations used in European association studies are often classified as 
“Caucasian”. In its original sense the term Caucasian (Caucasoid, Europoid) refers to 
the general physical type of populations from Europe, North Africa, and large parts of 
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Asia. In common use, especially in American English, the term is usually restricted to 
Europeans and other light-skinned populations within and around Europe, and may 
be considered equivalent to the varying definitions of white people.   
Inconsequent use of terminology contributes to population stratification and lack of 
replicability in genetic association studies. Being aware of this issue, the population in 
our studies met stringent definition criteria, as described in the Methods section. 
 
Genetic heterogeneity 
Genetic heterogeneity is defined as the phenomenon that a single phenotype may be 
caused by any one of a multiple number of alleles or non-allelic (locus) mutations. 
One of the major difficulties in complex disease is the potential for genetic 
heterogeneity and differential interaction with a plethora of modifying genes.  This 
issue is particularly serious for case - control designs in genetic association studies.  
It is the rule, rather than the exception, that datasets contain assortments of different 
aetiologies. Restricting ascertainment to a single ethnic group facilitates a reduction 
in this issue. 
Even our own TLE dataset is not free from heterogeneity. TLE, by definition, contains 
a number of different aetiologies. For that reason, phenotype studies were conducted 
in an attempt to segregate particular subgroups of the TLE (papers I and IV). We 
found that the phenotype of TLE patients with hippocampal sclerosis (MTLE-HS) and 
the phenotype of TLE patients who had experienced febrile seizures in childhood 
(TLE-FS) could be segregated from other TLE, indicative of the existence of a 
specific aetiopathology.  In our genetic studies, we looked specifically at genetic 
associations in these subgroups. Consequently, our phenotype study also served as 
a quality control for our genetic association studies. 
 
Interpretation problems of genetic association studies 
Despite a growing consensus that complex diseases, such as TLE, probably rely on 
a convoluted interplay between several, if not many, different genes, the idea still 
persists that diseases are usually caused by, at most, one single gene. This single 
gene is believed to be mainly responsible for the development of the disease, while 
others, so called modifier genes, may regulate/alter its expression and hence lead to 
penetrance variations (Greenberg et al., 2011).  
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The rationale for this gross oversimplification may be the fact that the analysis of 
such a complicated genetic interplay poses extreme challenges to our human 
conceptual skills, as well as data processing and interpretation. In multiple gene 
association studies or GWAS, the quantity of data generated is of such an immense 
dimension that difficulties arise even for single gene interpretation.  In our association 
study, we established a multivariate analysis to explore specifically the possibility of 
allele combinations predicting disease. Since our study dealt with only 2 genes, the 
approach is rather simple, but is, nevertheless, more advanced than a simple single 
SNP association analysis. Tools for calculation and interpretation of gene-gene 
interactions in multiple gene association studies or GWAS are necessary to find 
common denominators of complex diseases like TLE.  
 
2.2.8 Regulatory and Ethical Considerations 
Handling of clinical patient data and blood/DNA was conducted in accordance with all 
applicable regulations, including, where relevant, the Declaration of Helsinki, June 
1964, as modified by the 48th World Medical Association, Republic of South Africa, 
October 1996. 
 
Ethics Committee 
The protocol was reviewed and approved by the regional ethical committee (REC) 
before patient recruitment. 
The REC reviewed and approved informed consent forms (ICF) and any other written 
information provided to the patient prior to any enrolment of patients. 
 
Informed Consent 
The Study Physician or his/her designee informed the subjects of all aspects 
pertaining to the subject’s participation in the study. 
The process for obtaining informed consent was in accordance with all applicable 
REC and regulatory requirements. The investigator, or his/her designee, and the 
subject both had to sign and date the ICF before the subject could participate in the 
study.   
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Data Security 
Access to the data at the study site, DNA extraction laboratory, DNA Screening 
Centre, and the National Hospital of Oslo Norway was strictly controlled.  Data 
containing the personal identification of the patients were kept in a separate file at the 
study site.  The personal patient information was not transmitted to the extraction 
laboratory, the screening centre, or to any other third party. 
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2.3 Immunohistochemical studies on human hippcampal slices 
2.3.1 Human subjects and definition issues 
Patients with medication-refractory TLE were selected for surgery after phased 
clinical and electrophysiological assessment at Yale New Haven Hospital. Yale New 
Haven Hospital has a long tradition in evaluating epilepsy patients, and the 
Departments of Laboratory Medicine and Neurosurgery at Yale University School of 
Medicine embrace one of the world’s largest brain banks for histopathological and 
molecular biological analyses of tissue derived from epilepsy patients. Patients 
selected for surgery underwent anteromedial temporal lobectomy, including resection 
of the hippocampus, according to standard procedures (Spencer and Spencer, 
1991). Tissue used in this study was obtained after informed consent and with 
approval of the institutional human investigations’ committee at Yale University.  
Hippocampal slices from TLE patients with hippocampal sclerosis (MTLE) and from 
those without sclerosis (non-MTLE) were randomly selected for this study. Random 
selection in this context means that the patients were not chosen on the basis of any 
clinical characteristics, but only on the basis of standard histology, showing either 
hippocampal sclerosis or not. Hippocampal sclerosis is defined by neuronal loss in 
distinct subfields of the hippocampus formation, mainly CA1 and the hilus, with 
relative sparing of CA2, in addition to astrocyte proliferation, granular cell dispersion, 
et ceteral. A somewhat critical point, which is often neglected, is the fact that tissue 
obtained from patients without hippocampal sclerosis is commonly described as 
“healthy” (non-sclerotic) control tissue. In fact, this is not absolutely correct.  This 
control group may represent a mixed population of patients with different pathological 
features; some may present with mesial temporal mass lesions, while others may not 
show any obvious histopathological alterations at all. The only feature shared by this 
control population is seizure focus in the mesial temporal lobe. As the general 
research society usually does not distinguish between these entities, some authors 
have formulated nomenclatures to discriminate between them: The Yale group 
usually distinguishes between MaMTLE (mesial temporal lobe epilepsy on the basis 
of mass lesion) and PMTLE (pseudo-MTLE, without any obvious pathological 
changes in the hippocampus). For practical reasons, differentiation between MTLE 
and non-MTLE predominates and was also used in our histopathological study. 
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However, strictly speaking, differentiation should also be between subgroups within 
non-MTLE, especially for quantitative analyses, in order to minimise confounders. 
 
2.3.2 Preparation of hippocampal slices 
Immediately after resection, the hippocampus was cut into 5 mm coronal slices. 
Slices were obtained from the mid-anterior portion of the hippocampus and were 
immersed (1 h) in a fixative containing 4 % formaldehyde and 15 % (vol/vol) 
saturated picric acid in 0.1 M phosphate buffer, pH 7.4 phosphate buffer (PB). They 
were then transferred to 5 % acrolein (Sigma Chemical Co, St. Louis, Mo) in PB (3 
h). Coronal sections were cut on a Vibratome and stored in a cryoprotection solution 
(FD Neuro Technologies, Catonsville, Md) at -20°C until further processing for Nissl 
staining and immunohistochemistry.   
 
2.3.3 Immunohistochemistry  
Vibratome sections of 50 μm thickness were incubated free-floating in the respective 
antibody solutions and processed according to the avidin biotin peroxidase protocol 
(Hsu et al., 1981) using the Vectastain Elite Kit (Vector Laboratories, Burlingame, 
Calif.) with diaminobenzidine as chromogen. The immunostained sections were 
mounted on gelatin-coated glass slides for examination by light microscopy The 
same method was also used to confirm specificity of the Kir4.1 antibody in fixed 
mouse tissue from cKir4.1-/- and wild-type mice. 
Rabbit affinity-purified polyclonal antibodies against Kir4.1 (#APC-035, Alomone 
	 	 	 	 !"	 $&*=	 @	 \	 *	 	ºC), dystrophin (#ab15277, 
^&	$=!	_`		!"	$&*=		\	*		ºC), and -syntrophin (Syn259 
kindly provided by S.C. Froehner, University of Washington, Seattle (Peters et al., 
1997)	 {	 !"	 $&*=	 	 \	 *	 	ºC), were used and mouse monoclonal 
*$|=$	!$*	}-dystroglycan (#B-DG-~	||&*		!"	$&*=	@	\	
at 4 ºC). 
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2.3.4 Semi-quantitative analysis 
Semi-quantitative analysis, using bright field microscopy, was used in order to 
determine differences in Kir4.1 astrocyte immunoreactivity between MTLE and non-
MTLE hippocampal specimens. Representative areas throughout all layers in the 
respective hippocampal subregions and in the hilus were marked, and 
immunoreactive astrocytes were counted per area. Mann-Whitney U-tests were used 
for statistical comparisons and a P value of <0.05 was considered statistically 
significant.  
Semi-quantitative analyses in light microscopy are challenging and prone to 
confounding factors. Areas of interest in the tissue sections should be marked by a 
person other than the investigator. The investigator should not know whether the 
probe belongs to the case (MTLE) or the control (non-MTLE) group. Although these 
principles were adhered to in our analysis, as the pathological changes in MTLE are 
relatively obvious, blinding is difficult to achieve. Moreover, enumerating objects of 
interest (astrocytes in the case of our study) depends on the alertness and 
experience of the investigator, and on the visual acuity of the investigator. Thus, 
different investigators may achieve different results, and the approach is, therefore, 
rather subjective. 
It is important to keep in mind that data obtained from human hippocampus tissue 
are, in all likelihood, not representative for the general TLE population, as patients 
selected for operation embody a kind of “end point” of a long-standing epileptogenic 
course. The most characteristic features of the sclerotic hippocampus, which are 
neuronal cell loss and gliosis, are accompanied by a multitude of molecular changes 
in glia, including the changes reported in this thesis. However, the aspect which 
remains elusive is the timeline of the impact of these changes and whether they 
represent causes or consequences of the epileptogenic process. 
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3. Summary of results 
3.1 Paper I 
Heuser K, Taubøll E, Nagelhus EA, Cvancarova M, Ottersen OP, Gjerstad L. 
Phenotypic characteristics of temporal lobe epilepsy: the impact of 
hippocampal sclerosis.  
Acta Neurol Scand Suppl. 2009;(189):8-13 
 
The aim of this introductory study was to explore phenotypic characteristics of 
patients with MTLE-HS and to compare them with other TLE patients who did not 
present with hippocampal sclerosis.  
The study was established on the basis of a large database, including 218 
Norwegian TLE patients, generated from standardised patient record forms which, in 
turn, had been derived from the GenEpA project (see Materials and Methods).  
We identified phenotypic characteristics that distinguish MTLE-HS from other TLE, 
and thus reinforce the theory that MTLE-HS may constitute a unique entity. This 
study provided a basis for the subsequent genetic association studies on subgroups 
of TLE and also served as quality control regarding our study population.
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3.2 Paper II 
Heuser K, Nagelhus EA, Taubøll E, Indahl U, Berg PR, Lien S, Nakken S, Gjerstad L, 
Ottersen OP.  
Variants of the genes encoding AQP4 and Kir4.1 are associated with 
subgroups of patients with temporal lobe epilepsy.  
Epilepsy Res. 2010 Jan;88(1):55-64 
 
This candidate gene study aimed to investigate whether variants of the genes 
encoding AQP4 and Kir4.1 are associated with TLE or subgroups of TLE. For that 
purpose, DNA from 218 Norwegian patients with TLE and 181 ethnically-matched, 
healthy controls were included and single nucleotide polymorphisms (SNPs) for 
KCNJ10 (Kir4.1 gene) and AQP4 were identified via HapMap and/or resequencing. 
For the TLE cohort as a whole, explorative multivariate analysis indicated a 
combination of several associated SNPs in KCNJ10 and AQP4 genes. However, the 
strongest association was found by single SNP and explorative multivariate analysis 
in the TLE-FS subgroup, with seven SNPs in KCNJ10 and one SNP between 
KCNJ10 and the neighbouring gene, KCNJ9.  
We concluded that variants of the KCNJ10/KCNJ9 and AQP4 genes are likely to be 
associated with TLE, particularly TLE-FS. 
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3.3 Paper III 
Heuser K, Hoddevik EH, Taubøll E, Gjerstad L, Indahl U, Kaczmarek L, Berg PR, 
Lien S, Nagelhus EA, Ottersen OP.  
Temporal lobe epilepsy and matrix metalloproteinase-9: a tempting relation but 
negative genetic association.  
Seizure. 2010 Jul;19(6):335-8. 
 
Matrix metalloproteinase-9 (MMP-9), a proteinase that cleaves extracellular matrix 
molecules, has been proposed as having a critical role in aberrant synaptic formation 
in the hippocampi of patients with TLE.  
This case-control study was designed to identify possible variants of the MMP-9 gene 
associated with TLE. A genetic association analysis was conducted in which 218 
Norwegian patients with TLE and 181 ethnically-matched controls were compared. 
We also studied associations within two subgroups of TLE-- MTLE-HS and TLE-FS. 
SNPs were selected from HapMap and dbSNP databases for the MMP-9 gene on 
chromosome 20, and standard haplotype analysis and multivariate explorative 
analysis were used. 
We found no statistically significant associations between the selected SNPs in the 
MMP-9 gene with TLE, or subgroups thereof. 
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3.4 Paper IV 
Heuser K, Cvancarova M, Gjerstad L, Taubøll E.  
Is Temporal Lobe Epilepsy with childhood febrile seizures a distinctive entity? 
A comparative study. 
Seizure. 2011 Mar;20(2):163-6 
 
Sufficient evidence exists to conclude a genetic propensity for the occurrence of FS, 
and various studies confirm a link to TLE. These studies were reinforced by data from 
our own association study, outlined in paper II, which indicated genetic variants in 
TLE-FS. The aim of this paper was to test the hypothesis that TLE with childhood 
febrile seizures (TLE-FS) represents a distinctive subgroup among the TLE. 
On this basis, the question arose whether TLE-FS displays a phenotype that can be 
distinguished from other TLE. To address this issue, we compared clinical and 
epidemiological features from 102 TLE-FS patients with those of 105 TLE patients 
without FS. We also conducted logistic regression analysis to adjust for possible 
confounders caused by overrepresentation of patients with MTLE-HS in the TLE-FS 
group. This was reasonable, as MTLE-HS had been identified as a distinguishable 
subgroup in paper I.  
We identified several clinical features significantly associated with TLE-FS, and 
concluded that TLE-FS is a phenotype that can be delineated from other TLE.  
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3.5 Paper V 
Heuser K, Eid T, Lauritzen F, Thoren AE, Vindedal GF, Taubøll E, Gjerstad L, 
Spencer DD, Ottersen OP, Nagelhus EA, de Lanerolle NC..  
Loss of Kir4.1 potassium channels in hippocampus of patients with mesial 
temporal lobe epilepsy 
Manuscript submitted 
 
Malfunction or lack of the astrocyte potassium channel Kir4.1 is assumed to be 
associated with epilepsy. To investigate the distribution of Kir4.1, 
immunohistochemistry was used in hippocampus specimens from patients with 
refractory MTLE-HS and compared with equivalent specimens from patients with TLE 
without hippocampal sclerosis. Immunohistochemistry was also conducted in the 
same patient material on molecules presumed to be involved in astrocyte membrane 
anchoring of Kir4.1, such as dystrophin, alpha-1-syntrophin, and beta dystroglycan. 
We found that Kir4.1 immunoreactivity in astrocytes was significantly reduced in 
patients with hippocampal sclerosis, in comparison with patients without sclerosis. 
The loss of astrocytic Kir4.1 immunoreactivity was most pronounced perivascularly, 
and was restricted to gliotic areas. Loss of Kir4.1 expression was associated with 
|	|	=
*|\$	=	-syntrophin, suggesting disruption of the dystrophin-
associated protein complex. In contrast, differences between MTLE and non-MTLE 
were not observed for beta dystroglycan staining. 
The changes identified in patients with hippocampal sclerosis are likely to interfere 
with K+ homeostasis and may contribute to the epileptogenicity of the sclerotic 
hippocampus.  
 
 
 
 71 
 
4. Discussion 
 
4.1 Which tools should be chosen for unravelling complex 
diseases?  
 
Complex diseases cover a broad spectrum of human health. Genes are likely to 
control disease risk, and interactions between genes, or between genes and the 
environment, may also play an important role. Advances in human genetics could 
assist in optimising management of complex diseases, help to assess risk factors, aid 
in disease prevention, and be used to assess prognosis. Genetic studies have 
proved highly successful at detecting simple Mendelian diseases, where single gene 
mutations have large effects, but progress has been slow when it comes to detection 
of genetic factors in complex diseases, including the large majority of idiopathic 
epilepsies.  
Several genes have been discovered as being causative for rare epilepsy forms or 
related syndromes. However, to date, there is no consistent evidence that these 
genes contribute to a predisposition to the common epilepsies, such as TLE.  
An almost dogmatic consideration over the past two decades has been the belief that 
epilepsies are highly likely to be diseases of neuronal ion channels and/or receptors, 
which led to the term “neuronal channelopathies”. This assumption has probably 
prejudiced the search for alternative target genes in epilepsy and also restricted, at 
least in part, additional scientific approaches. 
However, the “neuronal channelopathy hypothesis” is currently under 
reconsideration, based on the fact that the search for causative neuronal ion channel 
genes proved unsuccessful for common epilepsies like TLE (Tan et al, 2004).  
The primary intention of this thesis was to investigate whether alternative “non-
neuronal” factors, more specifically the astrocyte targets AQP4 and Kir4.1 and the 
extracellular enzyme MMP9, could be involved in the development of TLE. 
Phenotype-genotype studies are auspicious for unravelling the genetic basis of 
complex diseases, including epilepsy. But such studies require a clear delineation of 
phenotypes. Thus, one objective of this thesis was to determine whether subgroups 
of TLE exist that could be delineated on the basis of clinical and demographic 
variables. This facilitated a quality control regarding our Norwegian TLE population, 
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and also formed the basis for our genetic case-control studies. Two subgroups were 
identified, and their classification resulted in the production of papers I and IV. As 
elaborated in the introduction, there is ample evidence in the literature for MTLE-HS 
to be considered a distinctive syndrome. However, the case differs for the subgroup 
of TLE patients who experience febrile seizures in childhood (TLE-FS). Despite a few 
indications in the literature, we found no earlier systematic approach for identifying 
TLE-FS as a separable subgroup. 
 
4.2 Does MTLE-HS represent a distinct disease entity? 
 
Clinical aspects of TLE have been studied extensively. However, there is a lack of 
analyses of phenotypic differences between MTLE-HS and other TLE-patients in a 
mixed cohort of operated and non-operated patients. Studies based solely on 
surgically-treated patients do not include the whole spectrum of MTLE-HS patients, 
as they concentrate only upon the most severe and medically-resistant cases. These 
gaps in our knowledge were addressed by the complementary study described in 
paper I.  
We found phenotypic differences between MTLE-HS and other TLEs with respect to 
seizure type and semiology, interictal depression, and age at epilepsy onset, as well 
as frequency and family history of febrile seizures. These findings suggest dissimilar 
biological backgrounds and support the existence of a specific aetiopathology in 
MTLE-HS.  
In our material, 26 % (56 patients) were diagnosed with MTLE-HS, in contrast to 74 
% (162) with other TLEs. At first glance, the number of MTLE-HS cases seems low. 
However, a plausible explanation for this may be found in our study design: Most 
literature referring to MTLE-HS frequencies are based on histological evaluation of 
patients that have been operated for the condition. These studies generally report a 
proportion of 50 % MTLE-HS cases. Close study of the literature, however, indicates 
a variation from 10 % (Goldsmith et al., 2002) to over 50 % (Semah et al., 1998). We 
believe that the wide range of incidence values is a reflection of the challenge of data 
ascertainment in epileptic disorders. Notably, deficiencies in patient reporting and in 
the diagnosis of seizures are known confounders, as are selection biases and 
classification problems (Sander et al., 1987).   
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4.3 Does TLE-FS represent a distinct disease entity? 
 
Sufficient evidence exists to conclude that there is a genetic propensity for the 
occurrence of FS, and an array of studies confirm a link to TLE, as elaborated in the 
introduction. Although specific genetic associations have not been found for the vast 
majority of FS and TLE, there is a growing consensus of opinion that genetics does 
have a role in both conditions. As both TLE and FS encompass strong clinical 
features, the combination of both in an individual may be a predictor for a genetic 
basis itself, and it is therefore reasonable to search for susceptibility genes and also 
phenotypic characteristics at the intersection of both conditions. 
The study conducted in paper IV was motivated by findings from our association 
study that indicated genetic variation among TLE patients who have had febrile 
seizures in childhood (TLE-FS) when compared with TLE without FS  (Heuser et al., 
2010) As a result of these findings we wanted to test the hypothesis that TLE-FS 
represents a further subgroup among the TLE. A literature search for supporting 
evidence identified a few other studies that indicated TLE-FS to be a unique entity, 
distinct from afebrile TLE (Umbricht et al., 1995; Abou-Khalil et al., 2007; Wieshmann 
UC et al., 2008). However, to the best of our knowledge, our study is the first 
systematic investigation of the phenotype of TLE-FS.  
We identified TLE-FS as a phenotype that can be delineated from other TLE on the 
basis of clinical and demographic features. Thus, TLE-FS may be considered to 
constitute a distinctive entity. However, none of the clinical characteristics could be 
regarded as specific. Further research, including genetic, clinical and animal studies, 
is needed in order to reach a firm conclusion. 
 
4.4 Alternative routes for epileptogenesis – might these occur via 
glial cells? 
 
As elaborated in the introduction, there is now a wealth of evidence that 
demonstrates that glial cells play an important role in the aetiology and pathogenesis 
of brain diseases, including the epilepsies.  
Normal brain function is critically dependent on efficient mechanisms for clearance of 
excess K+ from the ECS (Kofuji and Newman, 2004). A build-up of extracellular K+ 
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makes neurons hyperexcitable and may rapidly translate into epileptic seizures. 
Electrophysiological data suggest that MTLE may be associated with deficient K+ 
handling and have indicated possible perturbations of K+ transport through the family 
of inwardly rectifying K+ channels (Bordey and Sontheimer, 1998; Hinterkeuser et al., 
2000). 
Within the scope of this thesis, we have demonstrated that Kir4.1 is lost from 
perivascular endfeet in hippocampi of MTLE patients. This loss occurs specifically in 
sclerotic hippocampi and is most pronounced in area CA1 and the hilus (figure 6). 
Loss of Kir4.1 shows a precise spatial coupling to regions of neuronal loss and 
gliosis. Thus, vessels typically lose their Kir4.1 immunopositive sheath as soon as 
they enter a sclerotic region. 
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Figure 6: Distribution of Kir4.1 immunoreactivity in coronal sections of the hippocampus in 
patients with TLE.  
Shown is Kir4.1 labelling in subfields of the hippocampal formation from patients without hippocampal 
sclerosis (non-MTLE) (A, C, E, G) and from patients with hippocampal sclerosis (MTLE) (B, D, F, H). 
In non-MTLE cases Kir4.1 immunoreactivity resided in astrocytic somata (arrowheads in C, E, G), 
processes (double arrowheads in C), and perivascular endfeet (arrows in C, E, G). Hippocampi from 
patients with MTLE showed substantial loss of astrocytic Kir4.1 immunoreactivity in areas with 
neuronal loss and gliosis (D, F). Thus, the sclerotic CA1 were almost devoid of Kir4.1 labelling (F). The 
hilus showed changes that were somewhat less extensive than those observed in CA1 (D). Loss of 
perivascular Kir4.1 immunoreactivity was associated with reduced labelling of astrocytes. The 
subiculum in MTLE (H) displayed a labelling pattern on a par with that observed in non-MTLE (G). The 
sclerotic area in CA1 in MTLE is marked with dashed line (B). Vertical panels (C, E, and G) and (D, F, 
and H) are high-magnification fields of the respective areas in A and B. Scale bars: A, B, 1 mm; B-F, 
					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Our data also provide some insights into the mechanisms that underlie the observed 
loss of Kir4.1. Notably, the immunocytochemical analyses revealed that the changes 
in Kir4.1 distribution are associated with parallel changes in the distribution of 
=
*|\$	=	-syntrophin. The most salient explanation of this finding is that the 
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	 |	 \$&\	 -syntrophin is 
known to be a member (Kofuji and Newman, 2004).  If valid, this explanation implies 
that Kir4.1 is anchored to the DAPC, as has been reported previously (Waite et al., 
2009). The changes incurred by disruption of local anchoring mechanisms may have 
been accentuated by alterations at the transcriptional or translational level, as 
indicated by the reduced number of Kir4.1 positive astrocytes in the gliotic areas.  
Although the precise mechanism remains to be established, the loss of Kir4.1 from 
the hippocampus of MTLE patients is a finding of considerable interest, as this loss 
may be an important contributing factor to epileptogenesis. Our finding complements 
previous electrophysiological observations in MTLE hippocampi that have indicated 
deficiencies in K+ homeostasis. Recent data from our own laboratory clearly show 
that deletion of Kir4.1 in mice delays K+ clearance and interferes with K+ spatial 
buffering (Haj-Yasein et al., in press). Mice with deletion of Kir4.1 succumb to severe 
seizures at an early age (Djukic et al., 2007). Taken together, the available data 
indicate that the loss of Kir4.1 could be a key step in the cascade of events that 
culminate in the development of chronic epilepsy.  
 
4.5 Alterations in the dystrophin associated protein complex 
(DAPC) - associated with loss of Kir4.1? 
 
The changes in Kir4.1 labelling illustrated were mimicked by changes in dystrophin 
labelling. Notably, the perivascular labelling for dystrophin was lost once the vessels 
entered the gliotic areas in CA1 or hilus. Vessels in the granule cell layer and 
subiculum were associated with strong dystrophin immunolabelling in MTLE as well 
as in non-MTLE hippocampi.  
$!	 $*\	 *\	 *$|=
	 *|	 -syntrophin produced a pattern that was strikingly 
similar to that found after application of the antibody to dystrophin, and this was true 
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for sections obtained from MTLE patients as well as for sections from non-MTLE 
patients.  
Interestingly, labelling for beta-dystroglycan did not show any differences between 
MTLE and non-MTLE cases and no changes in the sclerotic hippocampal subfields. 
	$=$!	*\*	=
*|\$	=	-
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	}-dystroglycan persists is 
consistent with the idea that MTLE is associated with activation of an intracellular 
protease that cleaves dystrophin. It is interesting in this regard that excitotoxicity has 
been shown to induce activation of calpain, an enzyme with a known affinity for 
dystrophin (Araujo et al., 2010; Yoshida et al., 1992). Attesting to the clinical 
significance of Kir4.1, the human Kir4.1 gene (KCNJ10) is associated with epileptic 
disorders (Buono et al., 2004; Heuser et al., 2010). Moreover, it was recently 
reported that mutations in the KCNJ10 gene give rise to a syndrome consisting of 
epilepsy, ataxia, sensorineural deafness, and tubulopathy (EAST/SeSAME 
syndrome) (Scholl et al 2009; Bockenhauer et al., 2009) 
There is one basic limitation when investigating astrocyte targets that should be 
taken into consideration. Due to the fact that the interactions between neurons and 
glial cells are not fully understood, it is difficult to determine whether changes in glial 
cells in epileptic tissue are causes or consequences of the disease. 
 
4.6 Why do genetic association studies fail? 
 
Genetic association studies are regarded as powerful tools for discovering common 
variants in complex and common diseases. However, association studies have 
performed relatively poorly to date as has been widely described, including a cross-
disciplinary review that showed consequent replication in not more than 6 out of 600 
associations (Hirschhorn et al., 2002).  
This rather sobering realisation has led to the implementation of stricter requirements 
for adequate methodological approaches in genetic association studies over recent 
years, including in the epilepsy field (Tan et al., 2004).  
Medical journals have become more restrictive at publishing association studies that 
do not fulfil requirements such as clear population definitions, correction for 
population stratification, selection of appropriate control subjects (ethnically-matched, 
from the same geographical region etc.), sufficient sample size, and high biological 
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plausibility (the validity of the study has to be demonstrated in a meaningful scientific 
context) for the choice of the candidate gene.  
In particular, it is currently almost impossible to publish negative association studies. 
This restrictiveness is not necessarily advantageous, as it bears the risk of 
publication bias. Another important weakness that may evolve from insisting on a 
substantial sample size is that rare idiopathic diseases, including rare epilepsy forms, 
may not be considered for investigation, even though such studies may provide 
valuable information that is of relevance to specific issues. Furthermore, studies with 
large sample sizes often require collaboration across geographical and thus “genetic 
borders”, which may dilute phenotype specificity. 
The latter is a major challenge for archetypical GWAS with large sample sizes, which 
have become increasingly common in recent years. Although GWAS are considered 
highly promising and successful (Hindorff et al., 2009), they are not completely 
sacred, and the theory that GWAS would solve all the problems encountered in 
single gene association studies has not been proved after all. Indeed, the enormous 
quantities of data that are generated by GWAS seem almost impossible to handle, 
and separating the few “true” signals from the extensive background noise is a 
serious challenge. Methodological technology has not kept pace with the flood of 
genotyping data; exploring gene-gene interactions (epistasis) involves a heavy 
computational burden, and things get even worse when environmental factors are 
added in to the equation.  In fact, the abundance of data GWAS provides, may have 
confused our discrimination between true scientific and false discoveries. As GWAS 
seem to be in danger of becoming placeholders for all other approaches to detecting 
genetic risk factors for complex/common diseases, these difficulties should not be 
forgotten in our enthusiasm.  
In my opinion, single gene or few-gene association studies still have a place in 
genetic research, as long as the appropriate criteria are maintained. These guidelines 
were, on the whole, intended to adhere to in the protocol for our association studies, 
as is reflected by the following: we aimed to use a phenotype that had been defined 
as clearly as possible; we had an a priori hypothesis and a strong biological 
plausibility for our candidate genes; population stratification was minimised by using 
only Norwegian subjects with Norwegian ancestors for both cases and controls. In 
addition, and to meet some of the challenges illustrated above, we conducted 
phenotype studies to achieve statistical support for the selection of TLE subgroups 
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used in our association analyses and used multivariate analysis in searching for 
disease-predicting allele combinations. Although we were unable to identify any 
polymorphisms of the human MMP-9 gene that were associated with TLE or the 
subgroups TLE-FS and MTLE-HS (Heuser et al., 2010), our search for associated 
variants of the AQP4 and KCNJ10 gene proved successful (Heuser et al., 2010).  
However, our sample size was rather moderate, and bias caused by selection, self 
reporting, population stratification, and genetic heterogeneity may have resulted in 
type I errors in our Kir4.1/AQP-4 study. For similar reasons, the negative results of 
our MMP-9 association study may be a type II error. 
  
Association studies are based on the theory that common, low penetrance genetic 
variants could cause, or be associated with, common diseases. Indeed, some studies 
have identified a large set of genetic variants that contribute to a great variety of traits 
and common diseases. However, disappointingly, both individual and cumulative 
effects are far too small to explain earlier estimates of heritability.  Hence the 
“common variant – common disease” theory” for complex diseases has to be 
reconsidered.  
As highlighted by Maher, 2008, the search for heritability factors may fail due to: 
1) Limitations regarding the design of association studies, as outlined above.  
2) There may be hundreds or thousands of common variants with low penetrance 
that invoke heritability. We lack sufficient modelling skills to assess their cumulative 
effect, and it is doubtful whether such a model would have any relevant 
consequences for clinical practice. 
3) The DNA architecture contains multiple large stretches of DNA, ranging from 
thousands to millions of bases, which are deleted or duplicated. These segments, 
also termed copy number variations (CNV), may account for genetic variability. As 
with other types of genetic variation, they probably also play a role in the heritability 
of diseases (Stefansson et al., 2008). Technology for detecting CNV is currently 
being tested by a consortium called the CNV project (Wellcome Trust Sanger 
Institute, Cambridge, UK; http://www.sanger.ac.uk/humgen/cnv).  
4) Epistasis can be defined as the phenomenon of the interaction of genes. Effects of 
one gene can be modified by one or several other genes. Epistasis has been 
recognised as fundamentally important to understanding the functions of genetic 
pathways and evolutionary dynamics of complex genetic systems (Phillips P, 2008). 
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Little is known about these gene-gene interactions, and no technology exists to aid 
the search for effects caused by epistasis. 
5) Epigenetics: the mechanisms of epigenetics are discussed in more detail in the 
subsequent section. 
6) Another possible explanation for the unsuccessful search for inheritability in 
complex diseases may be simply the fact that our thinking is fundamentally wrong, 
and that other, currently unconsidered, factors are responsible or of greater 
importance. 
 
4.7 What makes us what we are? 
 
It is important to remember that we are not our genes. Our genome cannot fully 
determine everything that we are, think, do, look like, and neither can it be entirely 
blamed for our susceptibility to diseases. The functionality of our cells, our organism, 
and, in a broader term, our “body and mind”, depends on more than on a helix of 
acidic base-paired nucleotides. But what else makes us what we are? At this point in 
the discussion it may be tempting to drift off into religious or philosophical 
considerations. Although this may be particularly interesting, I prefer to leave this 
question unanswered. To return to applied science, the rapidly progressing field of 
epigenetics cannot be omitted from the discussion. Although already defined in 1939 
(that is, 14 years prior to the discovery of the molecular structure of the DNA) by the 
English biologist and geneticist Conrad Hal Waddington (1905-1975) as “the causal 
interactions between genes and their products, which bring the phenotype into 
being”, this field is really just at the beginning of its scientific journey. This is attested 
by the over tenfold increase in the amount of publications on this topic within the past 
decade (Portela et al., 2010). Epigenetics refers to the dynamic chemical 
modifications that occur to our DNA, as well as its subsequent association with 
regulatory proteins (Esteller M, 2008). To describe even the best recognised 
epigenetic modifications, such as DNA methylation, histone modifications, and 
nucleosome positioning, would go far beyond the scope of this thesis. All human cells 
share the same genetic information, but brain cells definitely have other duties than 
cells of, for example, the intestinal mucosa. This means that not every gene can be 
active in every cell all the time.  
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As genetics (from Greek genetikos/ genesis = origin) can be considered as the origin 
of life, it can also be claimed to be the origin of all living organisms, of the individual, 
the human with all its different characteristics, including the diseased one. This latter 
consideration is the reason why disease classifications consistently fail, due to the 
challenging act of drawing a line between disease and non-disease, and, probably 
even more difficult, in separating disease entities from each other. 
Genetic factors probably profile a continuum from healthy to diseased, and, in our 
context, from a “normal” brain, via a slightly excitable brain, to the hyperexcitable 
(epileptic) one. Moreover, environmental factors may cause disease under certain 
circumstances, such as, for example, a definite genetic predisposition.  
Recent advances in molecular genetics have added important value to our 
understanding of complex diseases, including the epilepsies. The discovery of 
monogenetic epilepsies has contributed to our knowledge of underlying 
aetiopathogenetic mechanisms of different epilepsy forms. Genetic tests have 
become available for different specific autosomal dominant familial epilepsies, and 
thus influence our clinical diagnostic practices. There is good reason to believe that 
considerable progress will also be made for common epilepsies with a complex 
genetic background, such as TLE and FS. 
However, to end with a quotation from Leonardo da Vinci: “All our knowledge has its 
origin in our perceptions”. Whether human perception or intelligence will ever be 
sufficient to uncover and understand the complex relationships between genes, gene 
products, external factors, and disease development currently remains unanswered. 
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5.  Conclusion 
 
 We conclude that it is possible to delineate phenotype subgroups among the TLE 
on the basis of demographic and clinical variables. 
 
o We confirmed that patients with MTLE-HS constitute a sufficient cluster of 
signs and symptoms to represent a distinctive syndromic entity. 
 
o We identified that TLE patients who suffered from early childhood febrile 
seizures (TLE-FS) represent a phenotype distinguishable from other TLE 
patients. 
 
 We conclude that variants of the KCNJ10 (Kir 4.1) gene and AQP4 gene are 
associated with TLE, particularly the subgroup of TLE-FS, supporting the 
suggestion that TLE-FS may constitute a unique entity, and that perturbations in 
water and K+ transport are involved in the aetiopathogenesis of TLE. 
 
 We conclude that there is significant loss of the potassium channel, Kir4.1, in the 
sclerotic hippocampus of patients with MTLE-HS, and that this loss may 
contribute to epileptogenesis in MTLE. 
 
 We hypothesise that deficient Kir4.1 in MTLE-HS is a consequence of altered 
anchoring via the dystrophin associated glycoprotein complex (DAPC).  
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6.  Future studies 
 
Within the period in which this thesis has been developed, we established an 
international network of research groups from both Europe and the USA. Parts of the 
research described in this thesis have, as noted, been conducted together with our 
collaborators at the Departments of Laboratory Medicine and Neurosurgery at Yale 
University School of Medicine, New Haven, CT, USA. Since then, this collaboration 
has been strengthened. In addition, we have established partnerships with groups in 
Bonn, Germany, Kuopio, Finland, and Utrecht, The Netherlands. Together with these 
European collaborators, we have formulated a framework for future projects, some of 
which are outlined below. 
 
Risk factors for temporal lobe epilepsy; gene association studies of different 
temporal lobe epilepsy subtypes in large TLE cohorts 
We plan to establish a set of association studies in well-defined subgroups of TLE, 
such as TLE-FS, MTLE-HS, drug-resistant TLE, and TLE patients with family 
members with TLE or other epilepsy types. These studies will focus on targets in 
brain glia. In order to increase statistical power and to exclude rare familial TLE 
subtypes, cohorts with large numbers of patients and matched-controls will be 
recruited from collaborating centres. 
 
Receptor-mediated Ca2+ signalling and gliotransmitter release 
Glial function is intimately regulated by cellular calcium signalling that underlies the 
specific form of "glial calcium excitability" (Nedergard and Verkhratsky, 2010). It has 
been shown that increased Ca2+ signalling in astrocytes results in paroxysmal 
depolarisation shifts (Tian et al., 2005), which characterises all focal epilepsies 
neurophysiologically, indicating a key role for astrocytes in seizure activity. 
Recent, two-photon imaging data from our own laboratory, show that AQP4 facilitates 
glial Ca2+ signalling in vivo and in cortical slices (Thrane et al., 2011). This might, 
therefore, contribute to glial Ca2+ hyperactivity, and hence the observed deleterious 
effects in the affected brain tissue. Our hypothesis is that glial cells in patients with 
MTLE-HS express pathologically increased Ca2+ signalling, leading to elevated 
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glutamate release and epilepsy. If confirmed, this could pave the way towards 
completely new treatment strategies for this serious condition. 
 
Defining factors that promote epileptogenesis in mouse models of MTLE-HS 
We predict that AQP4-deficient mice are less prone to development of seizures than 
wild type mice and display reduced astroglial Ca2+ activity. We will use wild type mice 
and mice deficient in AQP4 or alpha-syntrophin (lacking perivascular AQP4) in order 
to determine whether AQP4 modulates the development of epileptogenic insults. 
Specifically, mice will be monitored for the development of spontaneous seizures and 
we will assess astroglial Ca2+ activity. 
 
Assessment of the time course of alterations in Kir4.1 expression after status 
epilepticus (SE) in mouse model of MTLE-HS 
In the chronical phase after SE, ‘classical’ astrocytes with passive current patterns 
are no longer present in the sclerotic CA1 region, closely resembling the situation in 
human HS. This suggests the hypothesis that impairment of Kir4.1 function starts 
shortly after SE, during the latent period, and causes subsequent generation of 
spontaneous recurrent seizures. Quantitative assessment of Kir4.1 expression of 
astrocytes post SE will be conducted. Preliminary data show that astrocytes 
increasingly lose gap junction coupling during this period. Whether this alteration is 
accompanied by reduced expression of Kir4.1 is therefore of interest. 
 
Subgroup-specific pharmacoresistance in TLE  
Patients with TLE frequently display pharmcoresistance and often require temporal 
lobectomy in order to achieve seizure control. One of the most important future tasks 
in overcoming medical intractability is identification of distinguishable entities among 
the TLE and tailoring pharmacological treatment to the respective TLE groups. 
The extent to which different phenotypes of TLE are associated with 
pharmacoresistance to particular antiepileptic drugs (AEDs) has only been 
rudimentarily investigated.  
Our TLE patient database contains detailed information about use of AED, including 
start and stop dates for 16 different AEDs, a rating scale for response to treatment, 
and other information. These data could serve as a useful basis for a comparative 
approach.
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